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ABSTRACT 
Cancer is defined as abnormal cell proliferation with the potential of metastasis and is an increasing 
threat to global health as the population becomes older. Cancer is triggered by gain-of-function 
mutations in oncogenes and loss of function mutations in tumor suppressor genes. This leads to the 
breakdown of two important barriers against tumorigenesis-cellular senescence, which is permanent 
cell cycle arrest, and apoptosis, which is a programmed cell death. MYC is one of the classical 
oncogenes and its deregulation is observed in various types of cancer where it plays an essential role 
in tumor development. It has been more than three decades since MYC was discovered; however, the 
precise role of MYC in normal cells and in different types of cancer is still under intense research 
and debate. For example, it has been shown that MYC can overcome senescence induced by another 
oncogene, RAS, and RAS can override apoptosis triggered by MYC, leading to oncogenic 
transformation of primary rodent cells. However, there is no evidence indicating to which extent, this 
cooperation between MYC and RAS occurs also in human primary cells, since transformation of 
human cells requires several steps in addition to overcoming senescence and apoptosis. 
Therefore, in Paper I, to investigate cooperation between MYC and RAS in human primary cells, we 
used human BJ fibroblast cells where we established a double inducible RAS and MYC system (BJ-
RAS-MYC). In this system RAS expression is induced by doxycycline while MYC is expressed as a 
MycER fusion protein controlled by 4-hydroxytamoxifen (OHT) treatment. As expected, RAS 
induction triggered cellular senescence, as evidenced by increased senescence-associated β- 
galactosidase (SA-β-GAL) activity, enlarged cell size, arrested cell proliferation, increased 
expression of histone H3 lysine 9 trimethylation (H3K9me3), 21 and p16, and decreased 
phosphorylation of pRB. MYC induction preferentially triggered apoptosis, measured as increased 
cell death and cleaved PARP. Dual induction of RAS and MYC decreased H3K9me3 and SA-β-GAL 
but enhanced p16 level compared to RAS induction alone, suggesting MYC failed to completely 
overcome RAS-induced senescence. On the other hand, MYC-trigged cell death was not rescued by 
RAS induction, even when MYC activity was tuned down or MYC activation was scheduled at 
different times after RAS induction. Thus, MYC and RAS failed to cooperate to overcome each 
other’s fail-safe mechanisms, in which the main obstacle seemed to be MYC-induced cell death. 
Given the importance of p53 in regulation of apoptosis and that p53 was triggered upon MYC 
induction in our system, we knocked down p53 to try to rescue cells from cell death. Unexpectedly, 
p53 depletion (BJ-RAS-MYC-shp53) failed to overcome MYC-induced cell death although it 
rescued RAS-induced senescence. In conclusion, MYC and RAS did not cooperate to abrogate 
apoptosis and senescence, respectively, in human primary cells, even after p53 depletion, suggesting 
that additional oncogenic events are required to overcome senescence and apoptosis in this system. 
In has been reported that cancer treatments such as chemotherapy and radiation can trigger 
senescence in tumor cells. Hence, the concept of pro-senescence therapy has emerged as an 
alternative of anti-cancer therapy, especially for tumors resistant to apoptosis-inducing therapies or 
where conventional therapies cause severe side-effects. In Paper II, we explored the potential of pro-
senescence therapy in melanoma treatment. First we investigated the efficacy of eleven clinical and 
preclinical drugs as monotherapy in a senescence screen, using a panel of melanoma cell lines with 
different driver or mutations, such as BRAFV600E, NRASQ61R, PTEN, PI3K, p53 and CDK4. 
Following treatment, cell number, nuclear/cell size, EdU incorporation, intensity of H3K9me3, p53 
as well as HLA class I staining was measured using an Olympus scanR high-content imager system. 
We found that vemurafenib and trametinib induced senescence in some but not all BRAF-mutated 
cell lines, while palbociclib, crizotinib and BKM120 induced senescence most of cell lines 
irrespective of BRAF/NRAS mutation status. These results were confirmed using a additional 
senescence markers, such as analysis of SA-β-GAL activity, cell cycle distribution and 
phosphorylation of pRb.  Moreover, palbociclib and BKM120 also increased expression of several 
SASP factors and palbociclib and crizotinib enhanced expression of HLA class I, implying the 
potential of increased immunogenicity. 
We next addressed the question whether combination treatment could synergize with vemurafenib to 
overcome intrinsic and acquired vemurafenib resistance. Therefore, we performed a combination 
treatment senescence screen, combining vemurafenib and trametinib with the other drugs. The 
results showed that palbociclib, crizotinib and BKM120 synergize with vemurafenib to trigger 
senescence in both vemurafenib-sensitive and –resistant cells. In addition, we found that the 
combination of palbociclib with crizotinib further enhanced senescence including SASP factors of 
relevance for immune responses, again independent of BRAF/NRAS mutation status. We also 
looked at expression of molecules associated with recognition by T and NK cells. Palbociclib 
increased the expression of HLA class I and HLA class II, but also of PD-L1 and the NKG2D 
ligands ULBP 2/5/6 in several melanoma cell lines, and the expression of these molecules were in 
some cases further enhanced by combining palbociclib with crizotinib.  This indicates that 
palbociclib induced both positive and negative immune markers for CD8+ T cell and NK cell 
recognition in melanoma cells, implying possible benefit of using anti-PD-1 combination treatment 
to eliminate such cancer cells. 
Although it is clear that MYC is one of the most important players in tumorigenesis, there are, 
unfortunately, no selective MYC inhibitors available in clinic today. The main reason for this is that 
transcription factors like MYC are difficult to target due to their lack enzymatic activity and 
intrinsically disordered features. Since MYC function is dependent on interaction with its partner 
MAX, this motivates us to try to identify and characterize MYC inhibitors directly targeting the 
MYC:MAX interaction. Thus, in Paper III and Paper IV, we used a cell-based bimolecular 
fluorescence complementation (BiFC) screen, where MYC and MAX were fused with two parts of 
yellow fluorescent protein (YFP), only the close proximity of MYC and MAX can restore the 
fluorescent signal. We found six compounds (MYCMI-2, MYCMI-6, MYCMI-7, MYCMI-9, 
MYCMI-11 and MYCMI-14) potentially targeting the MYC-MAX interaction. This was validated in 
cells using the following assays: 1) split Gaussia luciferase (GLuc), where MYC and MAX are fused 
with two complementary fragments of GLuc; 2) in situ proximity ligation assay (isPLA), in which 
after primary antibodies binding, secondary antibodies conjugated with oligo were bound to the 
primary antibodies, and the close proximity assisted oligos ligation and followed by PCR, 
fluorescent probe to PCR products can be visualized; 3) U2OS-MycER system showed us that these 
compounds repressed MYC target genes. Among the six compounds, MYCMI-6 and MYCMI-7 
exerted the highest efficacies. We next investigated whether these molecules directly target 
MYC:MAX interaction in vitro using recombinant proteins in microscale thermophoresis (MST) 
assay, which is based on changes in the mobility of a fluorescent molecule in a temperature gradient 
upon binding of ligands/inhibitors). We also used surface plasmon resonance (SPR), which is a 
highly sensitive assay to determine the affinity between protein and ligand and to measure the kinetics 
of interactions. With both these assays, MYCMI-6 and MYCMI-7 were confirmed to inhibit MYC: 
MAX interaction via directly binding to MYC bHLHZip domain in the low micromolar range, 
which is more potent than previously reported MYC:MAX inhibitors. A difference between 
MYCMI-6 and MYCMI-7 was that the former did not affect MYC expression, while MYCMI-7 
decreased MYC protein, but not mRNA, level. The mechanism behind this is not clear. Furthermore, 
both MYCMI-6 and MYCMI-7 inhibited growth and induced apoptosis in a number of MYC-
dependent tumor cell lines, such as MYCN-amplified neuroblastoma and MYC-driven Burkitt’s 
lymphoma. MYCMI-6 reduced tumor cell proliferation in a mouse xenograft model of MYCN-
  
amplified neuroblastoma. In addition, MYCMI-7 reduced tumor burden in mouse models of MYC-
driven acute leukemia, triple negative breast cancer and MYCN-amplified neuroblastoma, and 
prolonged survival in the latter two models.  
It has been reported previously that MYC depletion by shRNA induced cellular senescence in 
melanoma with BRAF or NRAS mutation, suggesting that MYC inhibition could be used in pro-
senescence therapy. In Paper V, we evaluated the senescence-inducing potential of the MYC 
inhibitors MYCMI-6 and MYCMI-7, reported in Paper III and Paper IV, as well as the previously 
reported MYC:MAX inhibitor 10058-F4 (F4) and one BET inhibitor JQ1, which represses MYC 
transcription, in a panel of melanoma cell lines. In a senescence screen performed as in Paper II, 
MYCMI-7 triggered senescence in the majority of cell lines, and was more potent than F4. This was 
further validated in selected melanoma cells with BRAFV600E mutation, and the effects of F4, 
MYCMI-7 and JQ1 was compared. JQ1 mainly induced senescence; MYCMI-7 a mix of apoptosis 
and senescence and F4 preferentially triggered apoptosis. Among the three MYC inhibitors, only 
MYCMI-7 exerted a persistent proliferation inhibitory effect after drug removal. We also performed 
a senescence screen for the combination of the MYC inhibitors and the BRAFV600E inhibitor 
vemurafenib, MEK inhibitors (trametinib/selumetinib) and the CDK4/6 inhibitor palbociclib. The 
combination treatment of MYC inhibitors with vemurafenib/trametinib/selumetinib synergistically 
induced senescence and overcame vemurafenib/trametinib/selumetinib resistance. In addition, MYC 
inhibitors synergized with palbociclib to induce senescence in BRAFV600E- mutated cells. Thus, 
combining MYC inhibitors with BRAF, MEK and CDK4/6 inhibitors synergistically induced 
malignant melanoma senescence. 
The data presented in this thesis has shed further light on the function of MYC in normal and tumor 
cells, but also opening up the possibility of targeting MYC in pro-senescence therapy. 
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1 INTRODUCTION 
1.1 CANCER  
Cancer is defined as abnormal cell proliferation with the potential to invade into other parts of 
the body and has a major impact on society of the whole world. According to NIH statistics, 
in 2018, 1735 350 new cases of cancer are estimated to be diagnosed in the Unites States and 
609 640 patients will die from cancer (Siegel et al., 2018). Cancer is a genetic disease caused 
by mutations although epigenetic changes also play a role. Some types of cancer are 
hereditary due to germline mutations, and these often have an early onset. However, most 
types of cancer are due to somatic mutations and affect adults as a result of aging, stochastic 
events as well as environmental and other factors. From a molecular point of view, a normal 
cell is maintained in a homeostatic state due to several well-tuned self-control systems, 
involving a number of cell signaling pathways, sophisticated regulation of the cell cycle, 
different fail-safe mechanisms responding to different types of stress and a preset limited 
lifespan. The human body is built up by numerous different cell types that need to 
communicate with each other, and cell of the immune system adds an extra protective role to 
the whole organism. However, due to genetic and epigenetic aberrations, this state of 
equilibrium can become destabilized and the protection systems can be compromised, 
eventually leading to cancer development. Thus, in the first part of introduction, I will briefly 
present the concept of oncogenes and tumor suppressor genes, relevant cell signaling 
pathways, cell cycle regulation, cellular fail-safe mechanisms – apoptosis and senescence, 
tumor immunology, some tumor types of relevance for this thesis and current cancer 
therapies. As the second part, I will focus on senescence – one of the topics of this thesis – in 
relation to its biology and importance to cancer therapy. The last part will be dedicated to one 
of the best-known oncogenes, MYC - the other main topic of the thesis- in terms of its 
structure, regulation, biological functions and targeting strategies.  
1.1.1  Oncogenes and tumor suppressor genes 
 The famous discovery by Peyton Rous validated the possibility of a sarcoma in the domestic 
fowl transmitted to other fowl, which was the first discovery that tumor can be triggered by 
certain tumor-inducing agent after isolation and transduction, later termed as oncogenes 
(Rous, 1910, 1911). Oncogenes were first identified in avian and murine retroviruses, e.g. 
SRC, ERBB2, RAS and MYC. Later, researchers found cellular homologs of these 
oncogenes, which were named “proto-oncogenes”. Proto-oncogenes normally promote cell 
growth and division under a tight control, however, after mutation, they become oncogenes 
with the potential to cause tumors. Besides the previously mentioned receptor/non-receptor 
tyrosine kinases, small GTPases and transcription factors, there are also other types of genes 
promoting tumor initiation and progression, including programmed cell death regulators such 
as BCL-2 and mouse double minute 2 homolog (MDM2). Their oncogenic functions can be 
triggered by genetic alterations affecting either their protein level or structures or both. For 
example, it has identified ERBB2 oncogenic function via its amplification or kinase domain 
 2 
mutation, leading to it ligand-independent constitutive activation (Moasser, 2007). Therefore, 
oncogenes promote tumor progression with a gain of function. 
On the other hand, there are also another important group of genes suppressing tumor 
development, therefore named tumor suppressor genes (TSG). Tumor suppressor genes can 
function in different ways. They can work as transcription factors, such as p53 and 
retinoblastoma protein (pRB), and repress proliferation-related genes thereby arresting the 
cell cycle. Another type of TSGs are involved in activation of the DNA damage response 
(DDR) and DNA repair, for example BRCA1 and BRCA2. Moreover, they can trigger 
programmed cell death or dampen survival signals, such as FAS and phosphatase and tensin 
homologue (PTEN). In cancer, mutations in tumor suppressor genes cause loss of function.  
 
1.1.2 Cell signaling 
Cells respond to external triggers mainly through cell-surface receptors, which can transmit 
external signals into the cell interior via activation of different signaling pathways. There are 
different groups of cell-surface receptors, such as tyrosine kinase receptors (RTK), G-protein 
coupled receptors (GPCR), NOTCH receptors and etc. RTKs, as an example, are mobile 
laterally in the plane of the plasma membrane as monomers. Extracellular mitogens 
(epidermal growth factor (EGF), fibroblast growth factor (FGF) and vascular endothelial 
growth factor (VEGF), etc) can bind to corresponding RTKs (EGF receptor, FGF receptor 
and VEGF receptor, etc) and trigger their dimerization, leading to trans-phosphorylation of 
the intracellular domains of the receptors at tyrosine residues. Phospho-tyrosine can act as a 
binding site for intracellular proteins containing SH2 domains, leading to activation of 
downstream effectors, by which signals will be amplified and trigger different responses, 
such as cell proliferation, survival and migration. For example, in the presence of the growth 
factor EGF, the RTK EGFR is activated leading to recruitment of the adaptor protein GRB2 
and the guanine nucleotide exchange factor “son of sevenless” (SOS), which activates 
downstream RAS-signaling. With the assistance of SOS, GDP bound to RAS is released and 
replaced by GTP, leading to the activation of RAS GTPase activity. RAS in turn activates the 
downstream mitogen activated protein kinase (MAPK) pathway by disrupting RAF’s internal 
autoinhibitory mechanism by altering its conformation, leading to RAF phosphorylation by 
membrane-associated kinases, such as p21-activated protein kinase (PAK) and SRC, 
followed by activation of RAF serine/threonine-specific protein kinase function. This leads to 
the initiation of protein kinase cascade, including activation of mitogen-activated protein 
kinase kinase (MEK) and extracellular signal-regulated mitogen-activated protein kinase 
(ERK). Eventually ERK phosphorylates and activates many transcription factors, such as 
MYC and c-FOS, leading to transcription of proliferation-related genes and promotion cell 
proliferation (Adams et al., 2000; Leone et al., 1997; Sears et al., 1999; Sears et al., 1997; 
Shaulian and Karin, 2001). Therefore, MAPK pathway plays an essential role in cell 
proliferation. Moreover, GTPase activating proteins (GAPs), such as neurofibromin 1 (NF1), 
can replace GTP to GDP bound to RAS, causing the inactivation of RAS. Thus, NF1 is 
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considered as a tumor suppressor and over 1400 NF1 loss-of-function mutations are 
identified in cancer without (Ratner and Miller, 2015). 
In addition to the MAPK pathway, RAS also activates phosphoinositide 3-kinase (PI3K) 
pathway. PI3K are heterodimeric molecules located in the plasma membrane. PI3K 
phosphorylates its lipid substrate phosphatidylinositol-4, 5-bisphosphate (PIP2) to 
phosphatidylinositol-3, 4, 5-triphosphate (PIP3). The latter can attract and activate the 
serine/threonine kinase AKT. Upon its activation, AKT phosphorylates downstream effectors 
involved in many biological processes. For example, glycogen synthase kinase 3 (GSK3) 
is phosphorylated and inactivated by AKT. GSK3 is involved in many processes, such as 
promoting degradation of the WNT pathway downstream effector β-catenin and of MYC, as 
well as negatively regulating eukaryotic initiation factor eIF2B. Therefore, inactivation of 
GSK3 leads to derepression of the above-mentioned factors and subsequently promotion of 
cell proliferation. AKT, on the other hand, phosphorylates and inactivates pro-apoptotic 
protein BAD, leading to inhibition of apoptosis. Moreover, AKT can also influence protein 
synthesis through the activation of the mammalian target of rapamycin (mTOR) kinase, 
which accelerates protein translation. Therefore, the PI3K/AKT pathway favors cell survival, 
enhances cell proliferation, reduces apoptosis and increases cell growth. PTEN, which is a 
phosphatase preferentially dephosphorylating phosphoinositide substrates, e.g. PIP3, is a 
negative regulator of the PI3K/AKT pathway. This explains why genetic inactivation of 
PTEN commonly occurs in different types of cancer (Milella et al., 2015).  
 
1.1.3 Cell cycle 
 Cell proliferation is under a tight control by the cell cycle, during which a series of 
biochemical events are taken place. The cell cycle is divided into four distinct phases: the G1 
phase, during which cells increase in size and prepare for DNA synthesis; S phase, during 
which DNA replication occurs; G2 phase, a preparation phase for cell division; M phase, 
mitosis, during which chromosomes condense and segregate followed by cytokinesis when 
two daughter cells are formed. After cell division, cells can either reenter the cell cycle or exit 
the cell cycle into the G0 phase, where cells are quiescent until they are activated by another 
wave of growth factors. 
There are a variety of regulatory and operative proteins to assist this process. Firstly, the 
cyclin/cyclin-dependent kinases (CDKs) complexes, which are the ‘engines’ driving the cell 
cycle. The cyclins - a family of proteins that act as positive regulatory subunits controlling the 
CDKs - work in an autonomous, oscillating manner, varying in level throughout the cell cycle. 
Their partner proteins, the CDKs, is a group of protein kinases that modify substrates 
involved in cell cycle, are relatively constant in level, but require cyclins to bind and activate 
their catalytic functions. Since cyclins’ synthesis and breakdown define the precise timing of 
a specific stage, different cyclin-CDKs complexes are present and function differently in the 
cell cycle. During a typical cell cycle, cyclin D-CDK4/6 initiates the progression through the 
G1 to the S phase, and cyclin D breaks down in the beginning of S phase. Meanwhile, cyclin 
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E is synthesized at late G1 phase, binds to and activates CDK2 to function during late G1 and 
early S phase. Then cyclin A-CDK2 is formed and assists the progression from S to early G2 
phase. After switching partner, cyclin A-CDK1 takes over from G2 to early M phase. 
Following the breakdown of cyclin A, cyclin B-CDK1 facilitates M phase transition.  
Though cyclin binding is the rate-limiting step for CDK activation, phosphorylation by CDK-
activating kinase (CAK) is also needed for CDK activity. Further, CDK activity is repressed 
via tyrosine phosphorylation by WEE1, which can be removed by the CDC25 phosphatase, 
thereby de-repressing the CDK. Moreover, ERK can also phosphorylate the cyclin D-
CDK4/6 complex during G1 to S phase transition. 
On the other hand, there are also several different negative regulators of the cell cycle. First, 
there are two classes of CDK inhibitory proteins. The first class includes several CDK 
inhibitors, INK4 proteins (p15, p16, p18 and p19), which specially target CDK4/6, and the 
CIP1/KIP1 family (p21, p27 and p57), which inhibit cyclin:CDK2 and 
cyclin:CDK1complexes. For example, p16 can be induced by aberrant oncogenic signals, e.g. 
RAS (Rayess et al., 2012), after which p16 prevents monomeric CDK4/6 from binding to 
cyclin D (Hall et al., 1995; Parry et al., 1995; Serrano et al., 1993), and disrupts the pre-
formed cyclin D:CDK4/6 complexes (Adachi et al., 1997; Hirai et al., 1995). This prevents 
pRB from being phosphorylated and inactivated by cyclin D-CDK4/6, thereby maintaining 
pRB-mediated G1 arrest, as will be explained later. Moreover, p21 can be induced upon 
physiologic stresses, e.g. DNA damage, in which p21 ceases the activity of already-formed 
cyclin E:CDK2, cyclin A:CDK2, cyclin A:CDK1 and cyclin B:CDK1 complexes, thereby 
arresting the cell cycle until DNA is repaired or permanently (senescence) (Harper et al., 
1995). Another important factor is the retinoblastoma protein (pRB) (Weinberg, 1995), which 
regulates the G1-S checkpoint controlling entry into the S phase. pRB is in a hypo-
phosphorylated i.e. in an active state in non-cycling cells or during G1 cell cycle arrest. pRB 
interacts with and represses the transcription factor E2F, which control S-phase genes. During 
mitotic signaling, cyclin D-CDK4/6 phosphorylates pRB in late G1 phase followed by cyclin 
E-CDK2, resulting in hyper-phosphorylation of pRB, which inactivates pRB and releases it 
from E2F. In turn, E2F initiates transcription of S phase-related genes. However, the CDK 
inhibitor p16, when activated, is capable of maintaining pRB at hypo-phosphorylated state 
via the repression of CDK4/6, leading to cell cycle arrest at G1 and, if expressed permanently, 
to cellular senescence (Gius et al., 1999; Takahashi et al., 2007). In addition, pRB also 
contributes to maintenance of chromatin structure during mitosis, protecting cells from 
chromosomal instability and aneuploidy, further stressing the importance of pRB as a tumor 
suppressor (Manning and Dyson, 2011). As a result of this delicate regulatory system, cell 
cycle is under strict control.  
 
1.1.4 Apoptosis and senescence 
When cells are exposed to noxious external agents, or are under oncogenic stress, attacked by 
the immune system or experience other detrimental signals, cellular fail-safe mechanisms, 
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such as cellular senescence and cell death, are triggered. Among different types of cell death, 
apoptosis is a well-studied programmed cell death, in which cells display shrinkage, 
chromatin condensation and fragmentation into apoptotic bodies. Apoptosis is a complicated 
and sophisticated process involving an energy-dependent cascade of molecular events. There 
are generally three classical apoptotic pathways: the extrinsic (death receptor) pathway, the 
intrinsic (mitochondrial) pathway and granzyme pathway, all of which converge on the same 
execution pathway eventually (Elmore, 2007).  
The extrinsic pathway is triggered by ligands bound to transmembrane receptors mainly of 
the tumor necrosis factor (TNF) receptor gene superfamily. As an example, during activation 
of the death receptor (FAS), the FAS ligand (FASL) binds to the receptor to recruit the 
adapter protein FAS-associated protein with death domain (FADD), and the latter bridges 
FAS to procaspase 8 to form the death-inducing signaling complex (DISC), leading to the 
activation (cleavage) of caspase 8. Caspases are cysteine-aspartic proteases that cleave 
specific protein substrates including other caspases. Activated caspase 8 in turn cleaves and 
activates caspases 3, 6 and 7, subsequently resulting in execution of the apoptotic process.  
The intrinsic pathway is stimulated by stresses, e.g. loss of growth and survival factors, 
shortage of nutrients or oncogene-induced stress leading to DNA damage. This affects the 
integrity of the mitochondrial outer membrane, which is controlled by the BCL family 
apoptosis regulators. For instance, the role of BCL family members BCL2 and BCL-XL is to 
keep channels in the mitochondrial membrane closed, while other members, like BAX, BAD, 
BAK and BID, enable the channels to open. Upon apoptotic signaling, the levels of BAX and 
BAK increase to exceed that of BCL2 and BCL-XL on the surface of the mitochondria, 
leading to the release of cytochrome c - the central actor of intrinsic pathway. Together with 
APAF1 protein, cytochrome c forms a structure in the cytoplasm called the apoptosome, 
which activates procaspase 9 to cleave procaspase 3, leading to activation of the executioner 
caspases 3, 6 and 7, thereby converging with the extrinsic pathway. Many apoptotic stimuli 
trigger the intrinsic pathway through the activation of p53, which upregulates the expression 
of BAX, BAK and PUMA, leading to apoptosis. In addition, FAS is a p53 target gene, 
thereby leading to the sensitization of the cells to the FAS ligand. Thus, p53 can bridge 
intrinsic and extrinsic apoptotic programs. 
A third pathway of apoptosis is triggered by cytotoxic T lymphocytes and natural killer (NK) 
cells when attacking target cells. In addition to the classic extrinsic pathway to activate death 
receptors on the target cells, these two types of killer cells can also attach to the target cells 
and inject granzyme B, a protease that directly cleave and activate procaspase 3 and 8, then 
converging with the other two pathways, as mentioned above. 
Another tumor barrier is cellular senescence, which will be described in more detail in section 
1.2.  
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1.1.5 Tumor immunology 
While apoptosis and cellular senescence are important cell-intrinsic barriers against 
tumorigenesis, the body has also developed a systemic defense system to cope with infection 
as well as tumor cells.  
 
1.1.5.1 The innate immune system 
The innate immune system provides rapid reaction against invasion of foreign organisms, 
virus-infected cells but also tumor cells. The innate immune system consists of various types 
of cells, such as macrophages, dendritic cells (DCs), neutrophils and natural killer cells (NKs). 
Many of them have phagocytic activity and recognize non-self-particles via pattern-
recognition receptors, such as toll-like receptor (TLR) family, which in turn, activates 
cytokine production. For example, after increasing vascular permeability via a number of 
secretory factors, such as TNF-α, IL-1 and IL-6 (Arango Duque and Descoteaux, 2014), 
macrophages can migrate to, engulf and destroy the foreign pathogens. Dendritic cells are 
derived from hematopoietic bone marrow progenitor cells, and initially are immature to 
prevent adaptive immune cells from attacking host cells. When they encounter foreign 
entities, they can efficiently phagocytize pathogens and process their antigens, migrate to 
lymphoid tissue for immune activation and rapidly become mature with secretion of 
interleukin 12 (IL-12) and type I interferons, leading to activation and proliferation of innate 
lymphocytes (Steinman and Hemmi, 2006). Natural killer (NK) cells are lymphocytes 
engaged in cytotoxicity and cytokine secretion, such as interferon-γ (IFN-γ), TNF-α, C-C 
motif chemokine ligand 2 (CCL2), CCL5 and chemokine (C-X-C) motif ligand 8 (CXCL8), 
to recruit other immune cells. Besides, via secretion of TNF-α and FASL, NK cells can bind 
to DR5 and FAS receptors on target cells and induce the latter’s cell death. In addition, there 
are an abundance of activation receptors on NK cells, one of which is NKG2D with a number 
of stress-related ligands, such as MICA/B and ULBP family proteins, leading to the 
activation of NK cells to release of lytic granules toward target cells (Vivier et al., 2011; 
Zamai et al., 1998). Therefore, innate immunity does not require pre-education and offers a 
rapid array of defenses.  
 
1.1.5.2 The adaptive immune system 
Another type of immunity is called adaptive immunity, in which immunological memory is 
triggered after an initial response to a specific foreign antigen, leading to an enhancement of 
immune response upon a successive exposure of this antigen. Immunogenic antigens are, 
however, not limited to foreign antigens, but also can be host-derived, for example tumor 
antigens caused by gene mutations, so-call neoantigens (Schumacher and Schreiber, 2015). 
Both T and B lymphocytes play an important role in this process, including helper T cells (Th 
cells or CD4+ cells), cytotoxic T cells (CD8+ cells or cytotoxic T lymphocytes, CTLs), 
effector B cells and memory B cells. The activation of T and B cells first requires the 
processing of antigen by antigen-presenting cells (APCs), mainly macrophages and dendritic 
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cells. The processed antigenic peptides are loaded onto the specialized antigen-presenting 
domain of major histocompatibility complex (MHC) class II molecules, in humans called 
human leukocyte antigens (HLA), and migrate to the surface of APCs, where they are 
recognized specifically together with HLA class II by CD4+ helper T cells. This leads to 
activation of the helper T cell, which will start producing cytokines, such as IFN-γ and TNF-
α, leading to proliferation and differentiation of cytotoxic T cells. These in turn can kill target 
cells by triggering apoptotic signals within the target cells via both granzyme pathway and 
death receptor-mediated extrinsic pathway. A subtype of helper T cells will interact with B 
cells, resulting in production of effector B cells and memory B cells. The function of effector 
B is to manufacture corresponding immunoglobulin/antibodies against, which can be secreted 
into the circulation to defend the foreign invaders and cancer cells. Upon a second exposure 
of this antigen, memory B cells can rapidly generate effector B cells for antibody production. 
However, the activity of cytotoxic T cells is restricted by regulatory T cells (Treg cells) that 
express different inhibitory markers on Treg cells, such cytotoxic T lymphocyte-associated 
antigen 4 (CTLA-4) and lymphocyte activation gene-3 (LAG-3), leading to reduced T-cell 
proliferation and efficacy. Moreover, transforming growth factor beta (TGF-β) and IL-10 
released by Treg suppress proliferation of these T lymphocytes (Corthay, 2009). 
Another important component in both innate and adaptive immunity is myeloid-derived 
suppressor cells (MDSCs) from bone marrow precursors. Its immune suppressive function is 
accomplished by polarizing macrophages toward a tumor-promoting phenotype producing for 
instance VEGF and TGF-β that promote tumor metastasis, inhibiting NK-mediated 
cytotoxicity, repressing the activity of helper and cytotoxic T cells and recruiting Treg cells 
(Ostrand-Rosenberg and Fenselau, 2018).  
 
1.1.5.3 Tumor immune escape 
Because of the efficient surveillance by immune system, cancer cells have developed 
different strategies of immunoevasion. Cancer cells often repress the expression of MHC 
class I, thereby avoiding tumor antigen presentation to cytotoxic T cells. Moreover, they can 
also release soluble FASL or immunosuppressive cytokines (TGF-β and IL-10) to sensitize 
cytotoxic T cells or DCs to apoptosis (Neuzillet et al., 2015; Peter et al., 2015). In addition, 
tumor cells can also activate Treg to escape the killing by variety of T lymphocytes. Further, in 
order to inactivate T cells, similar to Treg  cells, cancer cells can stimulate immune checkpoint 
pathways by increasing expression of the cytotoxic T-lymphocyte–associated antigen 4 
(CTLA-4) and programmed death-ligand 1 (PD-L1), to dampen the function and proliferation 
of cytotoxic T cells. By these ways, cancer cells try to promote ‘immune escape’.  
 
1.1.6 Malignant melanoma and neuroblastoma 
I will next briefly introduce two types of cancer, melanoma and neuroblastoma, which are 
particularly related to my research, and how they are treated. 
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1.1.6.1 Malignant melanoma  
Due to its aggressiveness at the advanced stage, malignant melanoma is considered as one of 
the most deadly forms of cancer, and its incidence is increasing worldwide. Sunlight exposure 
is one of main pathogenetic contributors. Cutaneous melanoma can be broadly classified in 
two categories: chronically sun damaged (CSD) and non-CSD melanomas, which also 
have difference in anatomical site of origin, mutation burden and types of oncogenic 
alteration. In CSD melanoma, due to long-term ultraviolet (UV) exposure, melanoma 
typically arises from the head, the neck and the dorsal surfaces of the distal extremities 
of older individuals, associated with mutations on NF1, NRAS, BRAFnonV600E or KIT. 
However, non-CSD melanoma originates from areas with less UV exposure, such as 
trunk, which is predominantly related to BRAFV600E mutations at melanocytic nevi 
(Shain and Bastian, 2016). In general, BRAFV600E occurs in 50% of melanoma and NRAS 
mutation accounts for 15-20% of cases, leading to aberrant signaling in MAPK pathway. 
Upon additional hits in driver genes such as PTEN loss and p53 mutation, these benign 
symmetrical nevi take an irregular shape and converts to a malignant stage. Excision surgery 
is always the first option to treat melanoma. But if the tumor is unresectable or have 
metastasized to other part of body, other therapies have to be applied. 
1.1.6.1.1 Traditional radiation and chemotherapy 
Chemotherapy includes the alkylating agents dacarbazine and its oral version-temozolomide, 
cisplatin, fotemustine and etc. Radiation therapy, utilizing high-energy X-ray or other 
particles, is another option to suppress tumor progression and as palliative therapy. However, 
both these treatment cause side effects and are not curative at advanced stages of disease.  
1.1.6.1.2 Targeted therapy 
Targeted therapy is designed for personalized therapy to specifically target cancer cells for 
each patient, based on the presence of critical driver mutations. Vemurafenib was the first 
drug targeting melanoma with BRAFV600E mutation, and has been a great success in treating 
these patients (Sosman et al., 2012). However, the therapeutic effect of vemurafenib is 
usually only transient due to development of drug resistance, which limits the application of 
vemurafenib in the clinic (Wagle et al., 2011). Inhibitors against MEK, a downstream effector 
of BRAF, is another new option, but also here tumors become resistant (Falchook et al., 
2012). Many resistance mechanisms have been suggested, such as reestablishment of the 
MAPK pathway, activation of the PI3K/AKT pathway or upregulation of RTKs (Das Thakur 
et al., 2013; Sullivan and Flaherty, 2013; Wagle et al., 2014; Welsh et al., 2016). In order to 
overcome resistance, combination therapy using trametinib (MEK inhibitor) together with 
dabrafenib (BRAFV600E inhibitor), or vemurafenib (BRAFV600E inhibitor) combined with 
cobimetinib (MEK inhibitor) have attracted attention, and have been approved by the Food 
and Drug Administration (FDA) for unresectable or metastatic melanoma exclusively, while 
many other combinations are undergoing clinical trials. 
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1.1.6.1.3 Immunotherapy 
Another recent option for melanoma treatment is immunotherapy, with the aim to invoke the 
patients’ natural defenses against cancer. Melanoma is considered as one of the most 
immunogenic types of cancer based on the following: many genes are mutated due to UV 
exposure, which is the main trigger of melanoma, causing the generation of a number of 
neoantigens. For example, researchers have identified several melanoma-specific antigens, 
such as melanoma antigen-encoding (MAGE) and NY-ESO-1. Moreover, melanoma patients 
acquire large amounts of melanoma-specific antibodies. In addition, metastatic melanoma is 
responsive to immune-stimulatory agents, including interferons and interleukin 2. Another 
hint is that patients with spontaneous regression have developed vitiligo (Jacobs et al., 2012) 
and the frequent observation of tumor infiltrating lymphocytes (TILs) into the tumor area, 
which is positively correlated with prognosis in many studies (Oble et al., 2009). Thus, 
immunotherapy for melanoma has drawn much attention and become the first-line therapy 
for melanoma with non-BRAF mutation. 
As mentioned above, CTLA-4 and PD-1 are two molecules responsible for the self-inhibitory 
pathways on T cells, so it is tempting to think that inhibition of either of these two molecules 
might enhance the patients’ immune response. FDA has approved three drugs, including 
Ipilimumab (anti-CTLA4 antibody), opdivo and pembrolizumab (anti-PD-1 antibodies), for 
melanoma treatment. In a phase 3 trial in resected stage III or IV melanoma, overall survival 
at 12 months in opdivo group is 70.5%, versus 60.8% in ipilimumab group (Weber et al., 
2017); while in another phase 3 trial in advanced melanoma, overall survival at 12 months in 
pembrolizumab group is 74.1% versus 68.4% in ipilimumab group (Schachter et al., 2017). 
However, the problem of resistance is inevitable in immunotherapy as well in advanced 
melanoma (Zaretsky et al., 2016). Further, it has been difficult to identify clinically reliable 
biomarkers for selection of patients that would benefit of immunotherapy. PD-L1 has been 
suggested as a promising biomarker for immunotherapy, but in several pivotal trials, PD-L1 
negative patients also responded to treatment to a moderate or even better extent, implying 
the involvement of other unknown mechanisms for sensitivity to this treatment (Robert et al., 
2015; Weber et al., 2015).  
 
1.1.6.2 Treatment on neuroblastoma 
Neuroblastoma, which is a childhood tumor derived from the neural crest during 
development, is the most common extracranial solid tumor for children, accounting for 6-10% 
of all childhood cancers. The tumor is due to uncontrolled proliferation of immature 
neuroblasts of the peripheral sympathetic nervous system (Brodeur, 2003). The cancer can 
occur anywhere along the peripheral nervous system and in about 50% of the cases it starts in 
the adrenal gland in the abdomen, causing a swollen belly and constipation. MYCN 
amplification is strongly correlated to the severity of the disease (Seeger et al., 1985). It has 
also been reported that mutations in the ALK and PHOX2B genes, as well as deletion of 
certain loci of chromosome 1 and chromosome 11, are associated with sporadic and familial 
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neuroblastoma (Molenaar et al., 2012). Low-risk patients, that often undergo spontaneous 
regression, do not receive therapy, but high-risk cases with high refractory rate and poor 
prognosis need more aggressive treatment. A variety of treatment options are available for 
high-risk cases, including several chemotherapeutic drugs, e.g. cisplatin and etoposide, 
followed by surgery, radiotherapy and maintenance therapy by cis-retinoic acid. However, 
the overall survival for high-risk group, most resistant to treatment, is 50% (Johnsen et al., 
2018). Novel treatment strategies are therefore urgently needed for these patients.  
 
1.2 CELLULAR SENESCENCE 
The second part of my thesis is about cellular senescence, particularly premature senescence 
in cancer biology.  
Senescence is characterized by irreversible cell cycle arrest, irrespective of the presence of 
growth factors. Unlike cells undergoing apoptosis or quiescence, senescent cells have a high 
metabolically activity, possess increased β-D-galactosidase activity, are phenotypically 
enlarged, have remodeled their high order chromatin structure and exhibit a senescence-
associated secretory phenotype (SASP), as summarized in Fig. 1. 
 
 
Fig. 1. Causes and characterization of cellular senescence. 
Cellular senescence is, together with apoptosis, a main barrier against tumorigenesis, but is 
also involved in normal physiological cellular processes. For example, senescence occurs 
during mammalian embryonic development, and is engaged in tissue remodeling (Munoz-
Espin et al., 2013). Senescence also plays a role in wound healing and tissue regeneration 
(Chiche et al., 2017; Demaria et al., 2014). Senescent cells secret SASP factors consisting of 
proinflammatory factors, growth factors and protease, etc, to modify microenvironment and 
recruit immune cells. Further, it is implicated in aging and age-related pathologies resulting in 
accumulation of senescent cells, thereby compromising tissue function and depletion stem 
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cell pools (Childs et al., 2015).  
 
1.2.1 Replicative senescence and premature senescence 
Telomere erosion is one trigger of senescence, which is called ‘replicative senescence’ and 
associated with the cellular aging process. 
Telomeres, which are composed of the 5’-TTAGGG-3’ replicative hexanucleotide sequence, 
are located at the ends of chromosomes and are protected by shelterin complex protein and 
RNA transcribed from telomeres. During DNA replication of the lagging strand, DNA 
polymerase can only continue the duplication in the presence of Okazaki fragments, which 
requires RNA primers to start replication. This causes the so-called end replication problem 
since the ends of the chromosomes cannot be completely duplicated. This leads to successive 
shortening of the telomeres in each cell cycle. If telomeres get too short, the structure of the 
telomere/shelterin complex is compromised, leading to uncapping of the telomeres. The 
unprotected free DNA ends will induce DDR and then be recognized by DNA repair system, 
such as non-homologous end joining (NHEJ), homology directed repair (HDR), which can 
lead to end-to-end fusion of telomeres from different chromosomes (Sfeir and de Lange, 
2012). If two chromosomes are fused together, there will be two or more centromeres, and 
the latter will be pulled to opposite directions by the mitotic spindle afterwards, subsequently 
leading to ripping chromosomes apart at some random sites. Initial telomere erosion and 
chromosome breaks induce further DDR, which in turn triggers replicative senescence, also 
called mortality stage 1 (M1) during cellular aging. However, if cells bypass M1 due to the 
defect of cell-cycle checkpoint mechanism (p53/p21 or p16/pRB pathway), end-to-end fusion 
becomes more severe and breakage fusion-bridge accelerates, which eventually results in 
crisis (M2 stage). However, in rare cases, some M2 cells will survive with upregulation of 
telomerase and possess indefinite cell proliferation, which is called immortalization (Fridman 
and Tainsky, 2008; Shay and Wright, 2005). Cancer cells that have escaped replicative 
senescence are immortal, capable of growing indefinitely.  
On the other hand, senescence can also be triggered by variety types of acute stresses, which 
is called premature senescence and is the focus of this thesis. For example, aberrant activation 
of oncogenes like RAS can induce senescence, in this case so called oncogene-induced 
senescence (OIS). Besides OIS, premature senescence can also be stimulated by other types 
of stresses, e.g. UV irradiation, hypoxia or toxins etc.  
The main players in senescence induction and maintenance are two tumor suppressor 
pathways - the p53 pathway and pRB pathway (Collado and Serrano, 2010; Larsson, 2011). 
p53 functions as a tetrameric transcription factor that is highly unstable with a half-life of 20 
minutes in normal cells. It is degraded predominantly by the E3 ubiquitin ligase mouse 
double minute 2 homolog (MDM2). However, p53 protein level is increased upon many 
types of stresses post-translational modification- mainly phosphorylation (Horn and Vousden, 
2007). For example, uncontrolled RAS activity causes DNA replication stress, leading to 
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double stranded DNA breaks. This leads to recruitment of the DDR sensor ataxia-
telangiectasia-mutated (ATM), followed by the activation of checkpoint kinase 2 (CHK2). 
CHK2 in turn phosphorylates p53 at Serine 20, which is part of MDM2 binding site, resulting 
in displacement of MDM2 and p53 stabilization. Moreover, ATM/ ataxia telangiectasia and 
RAD3-related (ATR) can also phosphorylate MDM2 and suppress MDM2-mediated p53 
degradation. After p53 activation, its downstream effector p21 is induced to arrest the cell 
cycle by inhibiting CDK2 (Aird et al., 2013; Di Micco et al., 2006). Moreover, pRB is 
important for senescence induction, for example through repression of a subset of E2F target 
genes linked to DNA replication (Chicas et al., 2010). In addition, p16 can be induced by 
oncogenic RAS, resulting in inhibition of CDK4/6 thereby preventing pRB phosphorylation 
and inactivation, reinforcing pRB-mediated suppression of E2F activity and subsequently 
cellular senescence (Mason et al., 2004). Therefore, p16/pRB is considered as a crucial 
pathway in senescence induction via both pRB-mediated G1/S control and p16-triggered 
CDK block. Recently, it has been reported that upon oncogenic stress, ribosome biogenesis 
defects occur after which the ribosomal protein S14 (RPS14) accumulates in nucleus and 
suppresses the activity of cyclin D/CDK4 complex, leading to preservation of active state of 
hypo-phosphorylated pRB, which trigger senescence (Lessard et al., 2018). Further, pRB also 
has functions independent of E2F repression. One is through promoting degradation of S-
phase kinase associated protein 2 (SKP2) by recruiting it to its ubiquitin ligase CDH1. In this 
way, pRB induces accumulation of one of substrates of the ubiquitin ligase SKP2, p27, which 
in turn inhibits CDK2 and CDK1 and thereby reinforce senescence (Binne et al., 2007; Wang 
et al., 2010).  
In addition, it has been reported that not only highly proliferating tumor cells, but also slowly 
proliferating cancer stem cells can undergo senescence (Kuilman et al., 2010). Therefore, 
cellular senescence, particularly premature senescence, functions as a blockage of 
tumorigenesis. Induction of premature senescence has therefore been suggested as anti-tumor 
therapy (pro-senescence therapy). In the following, I will go through the senescence concept 
in more detail.  
 
1.2.2 Senescence and autophagy 
β-D-galactosidase was the first senescence marker to distinguish senescent cells from 
terminally differentiated cells or quiescent cells, and is widely used in senescence research 
(Dimri et al., 1995). Physiologically, this enzyme is activated as a eukaryotic hydrolase at 
pH4.0-4.5 in the lysosome (D'Azzo et al., 1982). However, in senescent cells, this enzyme is 
also active at pH 6 due to both increased amount and activity (Kurz et al., 2000). This can be 
measured by the addition of the artificial substrate X-GAL. However, SA-β-GAL activity is 
only a marker for senescence, its role in the senescence process seems dispensable (Lee et al., 
2006). Later on, researchers also found other components in the lysosome that can be used as 
senescence markers, including α-L-fucosidase and Sudan-Black-B specific staining of 
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lipofuscin (Georgakopoulou et al., 2013; Hildebrand et al., 2013). However, it remains 
unclear how the lysosome is functionally intertwined with senescence. 
Besides senescence, autophagy is another lysosome-linked cellular process. Under both 
physiological and stressful conditions, autophagy serves as an evolutionary ancient process to 
supply and maintain nutrients and energy by degrading as well as recycling damaged proteins 
and organelles. This is mainly regulated by autophagy-related ATG genes and the mTOR 
complex. Conceptually, both autophagy and senescence play important intrinsic roles in 
protecting cells from a variety of shared stimuli, including telomere shortening, DNA damage 
and oncogenic stress. Thus, it is tempting to assume that there is a crosstalk between these 
two cellular processes. Indeed, the role of autophagy has been explored in oncogene-induced 
senescence; in a HRAS-induced senescence model, Young et al. discovered that inhibition of 
autophagy via PI3K-mTOR pathway can delay senescence induction and block the protein 
synthesis process of SASP, indication a positive relation between senescence and autophagy 
(Young et al., 2009). This relationship was also supported by other studies (Huang et al., 
2014; Liu et al., 2014; Takasaka et al., 2014). Interestingly, it also has been documented an 
autophagic degradation of the nuclear lamina component lamin B, in particular during 
oncogene-induced senescence but not during starvation (Dou et al., 2016; Dou et al., 2015). 
However, other independent studies report a negative correlation between senescence and 
autophagy. For example, knockdown of ATG5 in mouse fibroblasts led to enhanced RAS-
induced senescence induction (Wang et al., 2012). One explanation of this discrepancy might 
be differential levels or types of autophagic activities in different cells. For instance, severe 
oxidative stress that exceeds the autophagic capacity can suppress autophagy and trigger 
senescence (Han et al., 2016; Tai et al., 2017). It can also be speculated that certain processes 
or components linked to autophagy are also required for senescence, or that there is a certain 
balance between two activities, implying a sophisticated relationship between senescence and 
autophagy. However, recent studies also question the role of autophagy in senescence. One 
study showed that autophagy is not involved in telomere dysfunction-induced senescence, 
and yet another study suggested that the two processes are not linked in glioma cells (Filippi-
Chiela et al., 2015; Mar et al., 2015). Overall, the relationship between senescence and 
autophagy remains unclear and needs to be investigated further. 
 
1.2.3 Senescence-associated chromatin remodeling 
Another characteristic of senescent cells is chromatin remodeling. During senescence, cells 
increase not only their cellular size, but also the nuclear size, which is linked to chromatin 
reorganization. This was first described by Narita and his co-workers, where they discovered 
the formation of senescence-associated heterochromatin foci (SAHF) (Narita et al., 2003). 
SAHF are distinct punctuate DAPI-dense foci, enriched in repressive histone marks, e.g. 
histone hypoacetylation, macroH2A, H3K9me3 and histone H3 lysine 27 trimethylation 
(H3K27me3). pRB is required for the formation of SAHF, and many pRB-regulated genes, 
e.g. cell cycle-related E2F target genes, are localized within the SAHFs. In turn, the 
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suppression of such genes in SAHFs promotes and stabilizes senescence. Furthermore, two 
repressive marks, H3K9me3 and H3K27me3, within the SAHFs are localized in non-
overlapping layers, surrounded by pericentromeric constitutive heterochromatin, leading to 
segregation of heterochromatin and euchromatin in these structures (Chandra et al., 2012). 
Unexpectedly, genome-wide occupancy profile by chromatin immunoprecipitation (ChIP) 
sequencing found no significant changes of these two repressive marks in the global 
chromatin landscape, except in certain specific genic regions, such as within the CDKN2A 
(p16) and CCNA2 (cyclin A2) loci. Moreover, depletion of these two marks failed to disrupt 
SAHF formation and vice versa, indicating that high-order heterochromatin formation is 
separable from epigenetic remodeling. 
The formation of SAHF has been further dissected by Peter Adams’s group. They found, 
firstly, that heterochromatin protein HP1γ and histone repressor A (HIRA) are recruited to 
promyelocytic leukemia (PML) nuclear bodies prior to SAHF formation. After binding of 
antisilencing function 1a (ASF1a) to HIRA and histone H3, this complex is capable of 
condensing individual chromosomes. SAHF is formed following integration of macroH2A or 
HP1γ (Zhang et al., 2007; Zhang et al., 2005). This is completed with further deposition of 
high-mobility group A (HMGA) proteins (Narita et al., 2006). However, HP1 proteins 
seemed to be dispensable for SAHF formation (Zhang et al., 2007). SAHF formation 
therefore remains elusive.  
Further studies also revealed that SAHF formation is a two-step event in ‘deep senescence’ 
(see further discussion about “deep senescence” below in section 1.2.5). First there is a loss of 
local interactions in certain regions of heterochromatin from the nuclear lamina, after which 
these regions form a senescence-specific spatial clustering of heterochromatin as a potential 
core of SAHF (Chandra et al., 2015).  
Due to the silencing capacity of SAHFs, it is considered to contribute to cell cycle arrest via 
repression proliferation-related genes (Narita et al., 2003; Zhang et al., 2007). An alternative 
interpretation is that SAHFs restrain the DNA damage response to avoid apoptosis, which 
would prolong the viability of senescent cells (Di Micco et al., 2011). However, due to 
observations that SAHF formation is not universal during senescence but cell context- and 
stimuli-dependent, SAHF cannot serve as a general senescence biomarker (Di Micco et al., 
2011; Kosar et al., 2011).  
Besides the distinct SAHF patterns, there are other alterations occurring in nucleus during 
senescence. As shown by Criscione et al. (Criscione et al., 2016), in general, long-range 
interactions are relatively lost and short-range gained within chromatin. Chromatin 
compaction occurs in the chromatin arms, leading to reduced size and poor accessibility of 
transcription machinery to these regions, resulting in gene suppression, while the centromeres 
expand in volume. The decompaction of centromemic DNA is also consistent with an earlier 
study from Swanson and colleagues (Swanson et al., 2013). They showed that at the early 
stage of senescence, DNA satellites in human and mouse centromeres are unraveled, which is 
termed as senescence-associated distension of satellites (SADS). This phenomenon appears 
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in human and murine cells both in vitro and in vivo, but it is not caused by nuclear 
enlargement and does not rely on canonical histone marks-mediated chromatin condensation. 
Further, in contrast to SAHFs it is stimuli-independent. The potential function of SADS could 
be to enhance the persistence of senescent state via blocking cell cycle, although this remains 
to be clarified. The enlargement of nuclear size observed during senescence occurs in parallel 
with an increase of nuclear protein content (De Cecco et al., 2011). 
Another important nuclear change during senescence occurs in nuclear lamins, which 
constitute the main structural component of nuclear lamina and are localized in the inner part 
of the nuclear envelope. There are generally two types of lamins, A-type (lamin A/C) and B-
type (lamin B). The former is mainly expressed in fully differentiated cells while the latter 
one is present ubiquitously in the lamina (Hutchison, 2002). In particular, it has been shown 
that rather than caspase-mediated degradation, the lamin B1 mRNA level decreases during 
senescence (Freund et al., 2012). The decrease in lamin B is suggested to contribute to the 
rearrangement of heterochromatin and SAHF formation. However, it remains controversial 
whether lamin B plays a causal role in senescence since lamin B knockdown merely slowed 
down proliferation rather than induced senescence in human fibroblasts (Dreesen et al., 2013).  
Moreover, chromatin budding also appears in late senescent cells, due to the loss of lamin B1 
and subsequently the integrity of nuclear envelope. These buddings fragments are expelled 
from nucleus into cytoplasm, are positive for γ-H2AX and H3K27me3, and form so-called 
cytoplasmic chromatin fragments (CCFs). The latter is targeted by autophagy machinery 
(Ivanov et al., 2013). 
 
1.2.4 Senescence and mitochondria 
One of important organelle, mitochondria, has also been reported to associate with 
senescence. In contrast to quiescent or apoptotic cells, senescent cells are metabolic active, 
characterized by increased oxygen consumption, mitochondrial potential, energy production 
and reactive oxygen species (ROS). Besides these senescence-associated features, emerging 
evidence has shown that mitochondrial dysfunction contributes to senescence induction. Back 
to the 50s, Harman et al. already proposed that mitochondrial free radicals contribute to aging 
(Harman, 1956). Nowadays, it is widely accepted that ROS is a senescence inducer. For 
example, exogenous hydrogen peroxide (H2O2) can generate endogenous ROS, including 
superoxide and hydroxyl radicals, leading to nuclear DNA damage and DDR-induced 
activation of the p53/p21 pathway, subsequently leading to cell cycle arrest (Duan et al., 2005; 
Zdanov et al., 2006). This increased steady-state level of ROS is considered as a positive 
feedback loop to maintain senescence, but other studies indicated that ROS production is 
dispensable after initiation of ROS-induced senescence (Passos et al., 2010). Apart from extra 
ROS generation, senescence is also linked to impaired mitochondrial dynamics, i.e. fission 
and fusion of mitochondria. For example, upon depletion of fission 1 (FIS1) - a mediator of 
mitochondrial fission – the fission process is compromised and the mitochondria remain 
elongated, which resulted in senescence (Lee et al., 2007). Additionally, mitochondrial fusion 
 16 
is implied to play a protective role when cell are stressed by stimulation of ATP synthase 
activity and prevention of mitochondrial depolarization, but the actual contribution is still 
under investigation (Gomes et al., 2011). Further, the electron transport chain (ETC) in 
mitochondria has also been implicated in senescence induction. For example, either 
pharmacological inhibition of ETC or genetic knockdown of the electron transporter can lead 
to senescence (Moiseeva et al., 2009; Yaguchi et al., 2007). Moreover, ETC-generated ATP 
also plays a role in senescence regulation. ATP depletion or exogenous AMP addition leads 
to disequilibrium of mitochondrial bioenergetics and activation of AMP-activated protein 
kinase (AMPK), followed by cell cycle arrest and senescence (Mihaylova and Shaw, 2011; 
Zwerschke et al., 2003). In addition, suppression of mitochondrial sirtuins (SIRTs) decreases 
the ratio of NAD+/NADH, leading to the activation of AMPK/p53-induced senescence, 
which accompanied with a distinct secretory phenotype and can be rescued by addition of 
pyruvate (Wiley et al., 2016). Therefore, mitochondria homeostasis is indeed closely linked 
to cellular senescence via the different factors mentioned above. 
 
1.2.5 Multi-step senescence model 
Rather than a static state, senescence is increasingly recognized to be a dynamic multi-step 
process (Baker and Sedivy, 2013; van Deursen, 2014). As summarized by Baker et al, cells 
are first temporally arrested in response to senescence inducers, so-called initiation of 
senescence response. In contrast to the conventional definition of cellular senescence as 
irreversible cell cycle arrest, this dynamic model provides more options for cells besides 
senescence, e.g. quiescence, terminal differentiation, cell death or re-entering cell cycle. In 
order to complete the transition from temporal to permanent senescence, more factors need to 
participate, such as persistent expression of tumor suppressor p53, or continuous p21/p16-
mediated inhibition of CDK-cyclin activity, or durable DNA damage response and so on. 
Without these events senescence cannot be reinforced or maintained. However, the accurate 
definition of ‘full’ senescence remains incomplete. It is still unclear what changes need to 
occur during maturation of senescence, e.g. the downregulation of lamin B1, the formation of 
SAHF or the decondensation of peri/centromric satellite heterochromatin, which contributes 
to massive alteration of transcriptome and secretome. Further, this ‘deep’ or ‘late’ senescence 
is also poorly defined due to lack of reliable biomarkers. As suggested, the striking increase 
of the transcription of transposable elements, e.g. members of L1, ALU and SVA, could be 
associated with ‘deep’ senescence (De Cecco et al., 2013; Wang et al., 2011). This leads to 
heterochromatin opening and loss of nuclear integrity, in another word, substantial alteration 
of genomic and epigenetic landscape, which could be one of the requirements for deep 
senescence.  
 
1.2.6 Senescence-associated secretory phenotype (SASP) 
The senescence-associated secretory phenotype (SASP) is one of the important characteristics 
to distinguish senescent cells from other non-proliferation cells, e.g. terminally differentiated 
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or quiescent cells. SASP has a heterogeneous profile, including inflammatory cytokines, 
chemokines, growth factors/regulators, proteases and insoluble proteins/extracellular matrix 
(ECM) components, which is cell context- and stimuli-dependent (Coppe et al., 2010; 
Munoz-Espin and Serrano, 2014; Sharpless and Sherr, 2015).  
Transcriptionally, SASP expression is mainly mediated by nuclear factor-κB (NF-κB) and 
CCAAT/enhancer binding protein-β (C/EBPβ) transcription factors, in response to different 
types of senescence stimulatory pathways, such as the RAF/MEK/ERK, p38MAPK and 
mTOR pathways (Chien et al., 2011; Freund et al., 2011; Kuilman et al., 2008). Apart from 
SASP transcription, mTOR signaling regulates SASP at translational level via stabilization of 
mitogen-activated protein kinase-activated protein kinase 2 (MK2), which in turn, avoid 
degradation of many SASP transcripts (Herranz et al., 2015). However, it remains unclear 
about the sophisticated mechanisms of SASP regulation. 
Due to the diverse composition of SASP (Hernandez-Segura et al., 2017), it is still under 
debate whether SASP exerts tumor suppressive or pro-tumorigenic effects. There are many 
SASP factors are associated with tumor suppression. For example, IL-6 is commonly 
involved in cell proliferation, survival and differentiation. In the senescent setting, it has been 
suggested to both reinforce senescence in an autonomous fashion and also trigger 
neighboring cells senescent in a paracrine manner (Kojima et al., 2012; Kuilman et al., 2008; 
Wan et al., 2014). In addition, CXC chemokine receptor 2 (CXCR2) is a member of the G-
protein-coupled receptor family, and it has many ligands, such as CXCL1and CXCL8, 
leading to activation of G-protein-mediated second messenger system. This receptor is 
associated with neutrophil migration to inflammation site (Futosi et al., 2013). CXCR2 has 
been reported to reinforce senescence in MEK-induced senescence in vitro via DDR-
dependent p53 activation (Acosta et al., 2008). Moreover, chemokine CCL5 is involved in 
recruitment of leukocytes into inflammatory sites, and proliferation and activation of NK 
cells (Maghazachi et al., 1996). Vilgelm et al. revealed the important role of CCL5 in tumor 
regression in two different settings of therapy-induced senescence (TIS). Upon combination 
treatment of aurora kinase A (AURKA) inhibitor and MDM2 antagonist, senescent 
melanoma secreted CCL5, which in turn, triggered immune surveillance by recruitment of 
NK, DC and T cells, leading to tumor clearance (Vilgelm and Richmond, 2015). In another 
model, CDK4/6- or AURKA-inhibitor treatment promoted TIS-induced CCL5, which 
resulted in recruitment of tumor-infiltrating leukocytes (TILs) and enhanced immunotherapy 
efficacy (Vilgelm et al., 2016). Further, the chemokine CCL2 has been reported to recruit 
CCR2+ immature myeloid cells (iMC) and to trigger their differentiation into macrophages, 
which remove senescent cells (Eggert et al., 2016). Furthermore, other proinflammatory 
cytokines, e.g. IL-1 and TGF-β, are capable of activating ROS-mediated DDR and 
p15/p21induction, leading to export of senescence in a paracrine manner (Hubackova et al., 
2012) (Acosta et al., 2008). IL-1α is reported to be the master regulator upstream of IL-6 and 
IL-8 via activation of inflammasome, and blockade of either IL-1 or inflammasome affected 
paracrine senescence, indicating the importance of IL-1 in the regulation of SASP and 
senescence (Acosta et al., 2008). Interestingly, Gr-1+ myeloid-derived suppressor cells were 
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shown to antagonize IL-1-signaling during docetaxel-induced senescence in a PTEN null 
prostate tumor model through secretion of IL-1receptor antagonist (IL-1RA) (Di Mitri et al., 
2014). TNFα is another SASP-related factor that can induce senescence by activation of p38-
MAPK and NF-κB pathways (Wajant et al., 2003) and recruit NK cells to target senescent 
tumor cells in vivo (Beyne-Rauzy et al., 2004; Ruscetti et al., 2018). 
However, SASP can be a double-edged sword since it has also been shown to promote 
tumorigenesis under certain conditions. Indeed, many of SASP factors are pro-inflammatory 
factors with paracrine function, which may cause detrimental effects in the long run, such as 
chronic inflammation, linked to degenerative diseases and cancer (de Visser et al., 2006; 
Glass et al., 2010; Grivennikov et al., 2010). Therefore, these aspects are considered the dark 
side of SASP (Coppe et al., 2010; Georgilis et al., 2018). For example, normal senescent 
fibroblasts in the microenvironment can induce epithelial cell proliferation and tumorigenesis 
(Krtolica et al., 2001); promote angiogenesis (Coppe et al., 2006); accelerate epithelial to 
mesenchymal transition leading to tumor cell invasion (Coppe et al., 2008). Moreover, due to 
the secretion of SASP, stromal cells may function as cancer-associated fibroblasts (CAFs) to 
communicate and facilitate tumor progression. For instance, senescent stromal cells can 
recruit suppressive myeloid cells (MDSCs) via SASP to antagonize anti-tumor-T cell 
function, leading to tumorigenesis (Ruhland et al., 2016). Additionally, an 
immunosuppressive microenvironment is generated by SASP in certain cases, which can 
undermine chemotherapy efficacy (Toso et al., 2014).  In addition, SASP composition and 
function is dynamic and cell context-dependent, and therefore even for the same factor can 
play either a positive or negative role in tumorigenesis depending on the context. One 
example is CXCR2, which reinforces senescence in KRAS-induced senescent fibroblasts as a 
tumor suppressor (Acosta et al., 2008). However, once premalignant cells escape senescence 
and develop cancer, these cells downregulate CXCR2 expression and recruit MDSCs with 
high oncogenic CXCR2 level, leading to tumor metastasis, like in pancreatic ductal 
adenocarcinoma (PDAC) with KRAS mutation (Steele et al., 2016). As mention above, 
CCL2 secreted by senescent pre-malignant hepatocytes recruit CCR2+ immature myeloid 
cells for clearance, but if these cells are mixed with malignant cells, the recruitment of 
CCR2+ immature myeloid cells will promote tumor growth (Eggert et al., 2016). 
Taken together, if and when SASP is good or bad for tumorigenesis is controversial and still 
under debate.  
 
1.2.7 Pro-senescence therapy 
The existence of senescence in tumors in vivo was first presented in four independent 
publications in 2005, in which senescent cells appeared in benign tumors but not in invasive 
cancer samples from prostate cancer, melanocytic nevi and indolent lymphomas (Braig et al., 
2005; Chen et al., 2005; Collado et al., 2005; Michaloglou et al., 2005). Prior to this it was 
debated whether senescence was an in vitro phenomenon, but this undoubtedly confirmed 
that senescence occurs in vivo and serves as a barrier against tumorigenesis. With increasing 
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evidence of senescence-mediated tumor suppression, the concept of pro-senescence therapy, 
also called therapy-induced senescence, has emerged a novel treatment strategy for various 
tumors, especially in tumors resistant to apoptosis-inducing therapy (Acosta and Gil, 2012; 
Larsson, 2011; Nardella et al., 2011). 
The tumor suppressive potential of pro-senescence therapy does not only rely on the 
irreversible cell cycle arrested feature of senescence, but also depends on SASP-triggered 
immune surveillance. The first evidence of the latter was that, after reactivation of RNAi-
regulated endogenous p53 in the mosaic mouse model of liver carcinoma, senescence was 
induced coupled with SASP consisting of different inflammatory cytokines that recruit 
macrophages, neutrophils and natural killer (NK) cells for clearance of senescent tumor cells 
(Xue et al., 2007). The recruitment of NK cells in this system was shown to be mediated by 
secretion of the SASP factor CCL2 (Iannello et al., 2013). Further, using a KRAS-driven lung 
tumor mouse model, a recent publication showed that upon combination treatment with 
CDK4/6 and MEK inhibitors, induction of senescence in the lung cancer cells led to 
recruitment of NK cells and tumor clearance via the SASP components TNFα and 
intercellular adhesion molecules-1 (ICAM-1) (Ruscetti et al., 2018). M1-like macrophages 
also play a positive role in tumor clearance upon p53 inhibition-triggered senescence in liver 
cancer (Lujambio et al., 2013). 
In addition to innate immune response, a study by Rakhra et al demonstrated that CD4+ T-
cells were required for the initiation of immune clearance in MYC-induced T cell acute 
lymphoblastic lymphoma or BCR-ABL-mediated pro-B cell leukemia mouse model (Rakhra 
et al., 2010). As mentioned above, triggering of senescence in melanoma cells upon dual 
inhibition of AURKA and MDM2 induced secretion of CCL5, leading to tumor clearance by 
activation of several immune cell types, including NK cells, DC, macrophages and T cells 
(Vilgelm and Richmond, 2015).  
Furthermore, pro-senescence therapy can also enhance the efficacy of immunotherapy. For 
example, CDK4/6 inhibition-induced senescence was reported to enhance anti-tumor 
immunity not only by suppressing the Treg population, but also by promoting cytotoxic T cell 
activity, which improved anti-PD-L1 immunotherapy (Goel et al., 2017). This also explains 
the enhanced antitumor activity with dual inhibition of BRAF and MEK combined with 
immunotherapy in melanoma (Hu-Lieskovan et al., 2015). Further, the potency of T cell-
activating therapy was improved together with AURKA-induced senescence therapy 
(Vilgelm et al., 2016). Thus, pro-senescence therapy indeed has the anti-tumor potential. 
However, as mentioned in section 1.2.6, SASP may create an immunosuppressive 
microenvironment, driving tumorigenesis and undermines chemotherapy efficacy (Ruhland et 
al., 2016; Toso et al., 2014). Thus, pro-senescence therapy should ideally be followed up by 
complementary treatment to eliminate senescent tumor cells. One theoretically conceivable 
therapeutic strategy is to provoke or reinforce immune response via the modulation or 
reprogramming of SASP. For example, in a mouse model of senescent PTEN-null prostate 
tumor cells, inhibition of JAK2/STAT3 (Janus kinase/signal transducers and activators of 
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transcription) can reprograme SASP, leading to a switch of secretion profile from 
immunosuppressive to immunostimulatory, resulting in further enhancement of 
chemotherapy efficacy, which supports the feasibility of pro-senescence together with 
immunotherapy (Toso et al., 2014).  
Although therapies based on elimination of senescent cells by immune system is an attractive 
approach, it is also challenging due to cell context- and stimuli-dependent heterogeneity of 
SASP and its interaction with the innate and adaptive immune system.  
Another option to eliminate senescent cells is via senolysis, which is an issue that has been 
raised recently to selectively kill senescent cells as adjuvant therapy to pro-senescence 
therapy. Actually, already back to 1995, Eugenia Wang proposed that senescent cells are 
resistant to apoptosis due to upregulation of BCL-2 (Wang, 1995), which inspired Kirkland’s 
group to try to target senescent cells via interfering with their anti-apoptotic, pro-survival 
mechanisms. After comparing the transcriptome of proliferative and senescent primary cells, 
they revealed the related pathways including BCL-2/BCL-XL, PI3K/AKT, p53/p21/serpines 
and different dependence receptors/tyrosine kinases (Zhu et al., 2015). The tyrosine kinase 
inhibitor dasatinib and PI3K inhibitor quercetin were identified as the first senolytic drugs, 
followed with inhibitors in BCL-2/BCL-XL pathway, such as navitoclax, A1331852 and 
A1155463 (Chang et al., 2016; Zhu et al., 2017; Zhu et al., 2016b). Related to quercetin, 
fisetin, has been identified as another senolytic drug with relatively low cytotoxicity 
(Yousefzadeh et al., 2018).  
In addition to apoptosis, there are also other synthetic lethal approaches targeting senescent 
cells. Since they are linked to high metabolic activity, senescent cells are susceptible to 
inhibition of specific metabolic factors, such as glucose transporters, glycolysis, energy 
sensor AMPK and pyruvate dehydrogenase kinase 1 (PDK1) (Dorr et al., 2013; Kaplon et al., 
2013; Wiley and Campisi, 2016). The interruptions to metabolic activity in turn destroy 
senescent cells. 
However, none of these apoptosis-targeting senolytic agents is universally effective to all 
types of senescent cells. Moreover, they inevitably have side-effects, for example, navitoclax 
also induces on-target thrombocytopenia, limiting their usage in clinic (Vogler et al., 2011). 
Furthermore, the lesson learnt from the acute clearance of tumor cells also implies some 
unexpected severe toxicity from senolysis via disrupting the physical functions of senescence 
in the body, like wound healing. Moreover, removing senescent cells from certain niches in 
the body such as stem cell niches, which are partially occupied by senescent cells, may 
induced stem cell proliferation, potentially leading to stem cell exhaustion or tumorigenesis. 
Thus, precautions are needed for the clinical use of senolysis therapy. 
In summary, pro-senescence therapy is a promising new strategy for cancer treatment, but 
likely needs to be complemented with other types of therapies, such as immunotherapy and/or 
senolytic therapy for long term effects. 
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1.3 THE MYC ONCOPROTEIN  
Apart from RAS, MYC is one of the best-documented oncogenes in cancer research. Due to its 
important role in cell proliferation, unconstrained expression of MYC is oncogenic.  
Deregulated expression of MYC occurs in a large fraction of all human tumors, in particular 
at advanced stages and is often associated with poor prognosis (Dang, 2012). In fact, MYC is 
the most frequently amplified locus in human cancer (Beroukhim 2010). For example, MYC 
amplification occurs in 40% of basal-like breast cancer, 34% in ovarian cancer, 30% in lung 
adenocarcinoma and 29% in colon cancer (TCGA, The Cancer Genome Atlas). Therefore, it 
is important to uncover the precise role of MYC both in cell biology and tumorigenesis. The 
overview of MYC is summarized in Fig.2, which will be introduced in detail in the following 
sections. 
Fig.2. The overview of MYC regarding to various stimuli, regulation of MYC, MYC structure and interactors and 
MYC biological functions. 
 
1.3.1 MYC structure and MYC interactors 
The MYC (c-MYC) oncogene was originally discovered in the genome of avian 
myelocytomatosis virus MC29 (v-myc), in the form of a fusion gene between the viral 
structural GAG gene and the MYC sequence (Bister et al., 1977; Duesberg et al., 1979). It 
was then discovered that v-myc was derived from the chicken cellular myc proto-oncogene 
(c-myc) via retroviral transduction (Vennstrom et al., 1982). Later researchers found 
homologues of the MYC gene in all vertebrate genomes and eventually further down in 
evolution to all major metazoan linages (Young et al., 2011). Also two other MYC family 
members, MYCN and MYCL were discovered in the early 80s. Based on the MYC-related 
sequence, amplified MYCN was originally identified in human neuroblastomas and MYCL 
was found in human small cell lung carcinomas (SCLC) (Kohl et al., 1983; Nau et al., 1985; 
Schwab et al., 1983). MYC is quite ubiquitously expressed in proliferating mammalian cells, 
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the expression of MYCN and MYCL is more tissue-restricted during development and in 
adults. Therefore, the MYC-family genes (collectively referred to as MYC hereafter) have 
attracted many researchers’ attention and is also the focus of this thesis. 
MYC binds specifically to DNA, which is attributed to part of its highly conserved basic 
helix-loop-helix/leucine zipper (bHLHZip) domain in the carboxyl-terminus (Murre et al., 
1989). The basic domain at the amino-terminal end of this region is responsible for specific 
binding to a DNA consensus sequence called E-box (CACGTG as similar sequences). The 
HLH and Zip motifs confer heterodimerization of MYC with another bHLHZip protein MAX, 
and this dimerization is necessary for DNA-binding and to serve as a transcription factor 
(Blackwell et al., 1990; Blackwood and Eisenman, 1991; Blackwood et al., 1992; Prendergast 
et al., 1991). The rest of the protein contains several evolutionary conserved so called MYC 
Boxes (MB) I-IV that also serves as interaction motifs with a wide range of proteins that play 
a role in MYC’s diverse functions (Cole and Cowling, 2008; Cowling and Cole, 2006; Meyer 
and Penn, 2008). The MYC boxes will be mentioned later in different sections, but briefly; in 
the N-terminus, MBI harbors critical sites for MYC modifications (Thr 58 and Ser 62) that 
regulate MYC activation and degradation (Hydbring et al., 2010; Sears et al., 2000; Seo et al., 
2008); MBII has been shown to interact with various of cofactors to regulate transcription, 
such as TRRAP and SKP2, and is required for transformation (Kim et al., 2003; McMahon et 
al., 1998; Park et al., 2002; von der Lehr et al., 2003; Wood et al., 2000); MBIII is related to 
transcriptional repression (Kurland and Tansey, 2008); and MBIV, which overlaps with the 
nuclear localization signal (NLS), is modified by acetylation and ubiquitylation and interacts 
with p300, FBXO28 and p27, and is implicated in MYC-driven transcription, transformation, 
apoptosis and G2 arrest (Adhikary et al., 2005; Bahram et al., 2016; Cepeda et al., 2013; 
Cowling et al., 2006).  
 
1.3.2 Regulation of MYC 
Unlike in cancer cells, MYC levels in normal cells are low even in proliferating cells. MYC 
is highly controlled both at the transcriptional and posttranslational levels (Levens, 2008). 
Regulation of MYC transcription is very complex, since it is activated by a number of 
mitogenic signal pathways, including receptor tyrosine kinases such as platelet-derived 
growth factor receptor (PDGFR) and epidermal growth factor receptor (EGFR), and 
downstream effectors RAS/RAF/MAPK, but also by WNT, Janus kinase/signal transducers 
and activators of transcription (JAK/STAT), sonic hedgehog (SHH), NOTCH and NF-κB 
pathways, which are often deregulated in cancer cells, leading to MYC overexpression 
(Clevers, 2004; Liu and Levens, 2006). MYC transcription is mainly initiated from two 
promoters, P1 and P2, where a variety of transcription factors can bind in response to 
different signals. Recently it is also reported that the MYC promoters are regulated from long 
distance by different super-enhancers, which are genomic regions containing multiple 
enhancers and collectively interacting with a variety of transcription factors (Cao et al., 2017). 
For instance, a CTCF-binding insulator region located 2 kb upstream of the MYC promoter, 
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has been shown to facilitate the interaction with a super-enhancer region around 2.8 Mb 
upstream of MYC (Schuijers et al., 2018). Moreover, MYC also represses its own expression 
through an autosuppression mechanism (Wierstra and Alves, 2008). 
In terms of MYC posttranslational modifications, both Thr 58 and Ser 62 are important 
phosphorylation sites (Hydbring et al., 2017). Ser 62 has been reported to be phosphorylated 
by ERK, CDK1 and CDK2 in response to different signals, which can transiently stabilize 
and activate the MYC protein, resulting in induced transcription and proliferation (Benassi et 
al., 2006; Hydbring et al., 2010; Sears et al., 2000; Seo et al., 2008; Seth et al., 1991; Yeh et 
al., 2004). Moreover, Ser 62 phosphorylation is a prerequisite for Thr 58 phosphorylation. 
Thus, Ser 62 phosphorylation “primes” for Thr 58 mediated by GSK3β (Gregory et al., 2003; 
Lutterbach and Hann, 1994; Sears et al., 2000). GSK3β in complex with AXIN (Beurel et al., 
2015), has been reported to recruit the PIN1 prolyl isomerase to restructure the 
phosphorylated Thr 58/Ser 62 region, thereby facilitating for protein phosphatase 2A (PP2A) 
to dephosphorylate Ser 62 (Yeh et al., 2004). MYC phosphorylated at Thr 58 is recognized 
by the F-box protein FBXW7, which is part of the SCFFBXW7 E3 ubiquitin ligase complex, 
leading to proteasomal degradation of MYC, growth inhibition and apoptosis (Arnold et al., 
2009). MYC degradation through this pathway is regulated by AKT, which phosphorylates 
and inactivates GSK3β, thereby preventing GSK3β/FBXW7-mediated degradation of MYC 
(Cross et al., 1995; Manning and Toker, 2017). Besides SCFFBXW7, other E3 ubiquitin ligases 
also ubiquitylate MYC, including SCFSKP2, HUWE1/HECTH9 and SCFFBXO28, which 
paradoxically activate MYC (Cepeda et al., 2013; Farrell and Sears, 2014; Kim et al., 2003; 
Thomas and Tansey, 2011; von der Lehr et al., 2003). On the other hand, mTOR has been 
implicated in regulating translation of MYC mRNA via both eIF4F and eIF4A-containing 
complexes (Bhat et al., 2015; Castell and Larsson, 2015; Wiegering et al., 2015; Wolfe et al., 
2014). Similar to autosuppression at mRNA level, MYC also has negative feedback at the 
protein level, for example, by MYC-induced upregulation of Max's Next Tango (MNT), 
which competes with MYC for binding to MAX (Menssen and Hermeking, 2002).  
 
1.3.3 MYC in transcription 
Upon binding to E-boxes at target gene promoters, the MYC:MAX complex can activate 
transcription by recruiting different transcriptional cofactors with different functions. For 
instance, it has been reported that MYC regulates transcription in part via the modulation of 
histone modifications. Nucleosomes are the fundamental building blocks of chromatin, 
composed of 147 base pairs of DNA wrapped around a histone octamer composed of two 
copies of H2A, H2B, H3 and H4 (Grewal and Moazed, 2003). When nucleosomes are 
densely packed together, heterochromatin is formed, which limits the binding of transcription 
factor to DNA templates. In order to loosen up chromatin to make it more accessible or when 
going from open to condensed chromatin, histone modifications play an important role. In 
general, histone acetylation relaxes the chromatin to facilitate transcription factors binding 
and initiate transcription, which is mediated by histone acetyltransferases (HATs) and 
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reversed by histone deacetylases (HDACs). In addition, histone methylations on different 
lysines also affect transcription, such as H3K4me2/3 is related to active genes, and H3K9me3 
and H3K27me3 are associated with gene repression, which are mediated through different 
histone lysine methyltransferase (HKMT), such as enhancer of zeste 2 (EZH2)  and 
SUV39H1 (Bannister and Kouzarides, 2011). Importantly, MYC is engaged in this process. 
For example, TRRAP, which is associated with several large HAT complex, such as the 
GCN5-containing STAGA and the TIP60 complexes, is recruited to chromatin by MYC via 
MBII, and plays a role in chromatin relaxation and transcription activation (Liu et al., 2003; 
McMahon et al., 1998; McMahon et al., 2000). MYC can also repress gene expression 
through less understood mechanisms. For example, by binding the transcription factor MYC-
interacting Zn finger protein-1 (MIZ-1), competes out the coactivator p300 and recruits 
HDAC3 and DNA methyl transferase 3a (DNMT3a) to the promoter regions of p15 and p21, 
leading to their repression (Brenner et al., 2005; Kurland and Tansey, 2008; Seoane et al., 
2001; Staller et al., 2001; Wu et al., 2003). 
Besides histone modifications, MYC is also shown to be involved in the alteration of 
nucleosome structure. The structure and positioning of nucleosomes can be altered by 
different ATP-dependent chromatin remodeling complexes, including five families in 
eukaryotes, i.e. SWI/SNF, nucleosome remodeling deacetylase (NuRD), ISWI, INO80 and 
SWR1. It has been reported that MYC-mediated transactivation requires the recruitment of a 
component of the SWI/SNF complex SNF5/INI1 at bHLH region, indicating SWI/SNF 
complex also assists MYC-mediated chromatin remodeling (Cheng et al., 1999).  
By binding to different cofactors, MYC is involved in different steps of the transcription 
process. MYC has been shown to promote transcription factor IIH (TFIIH) activity to 
phosphorylate on C-terminal domain (CTD) Ser 5 (S5) of RNA Polymerase II (RNAP II), 
leading to transcription initiation (Cowling and Cole, 2007). Recently, a role of MYC in 
transcription elongation has been suggested. After transcription initiation, RNAP II is pausing 
at approximately 30-50 bp downstream of transcription start site (TSS) of many genes. It was 
reported that binding of MYC:MAX to target gene promoters results in promoter clearance 
and elongation through the recruitment of P-TEFb (Bouchard et al., 2004; Eberhardy and 
Farnham, 2001, 2002; Rahl et al., 2010).  
MYC also recruits several E3 ubiquitin ligases to chromatin, including SCFSKP2, 
HUWE1/HECTH9 and SCFFBXO28, which ubiquitylate MYC in a proteolytic or non-
proteolytic manner, but also play a role in promoting MYC-driven transcription (Adhikary et 
al., 2005; Cepeda et al., 2013; Kim et al., 2003; von der Lehr et al., 2003). Recently, it was 
reported that this not only increases histone acetylation, but also transfers RNAP II-associated 
factor complex (PAF1C) to RNAP II to stimulate elongation (Jaenicke et al., 2016).  
Since the identification of MAX and the E-box binding activity of the MYC:MAX 
heterodimer, the consensus model has been that MYC is working gene-specifically, i.e. 
MYC:MAX complex is bound to specific E-box-containing genes to regulate transcription. In 
contrast, more recent studies suggested that MYC works as a global amplifier of transcription 
 25 
 
(Lin et al., 2012; Nie et al., 2012). However, other research groups challenged this theory. 
Bruno Amati’s group reported that MYC primarily acts through differential regulation of its 
direct target genes, and that global RNA amplification is an indirect effect of activation of 
these specific genes, which initiates a cascade of downstream events (Sabo et al., 2014). 
Martin Eilers´ group also confirmed that transcriptional amplification occurred as a result of 
MYC:MAX binding to a specific set of genes, that either leads to activation or repression of 
gene transcription, in part dependent on the interaction with MIZ-1  (Walz et al., 2014). 
Though these different models are still under debate, there is a general agreement that MYC 
plays an essential role of in regulating genes affecting many cellular processes, including 
cellular proliferation, growth, apoptosis, DNA damage and senescence.   
 
1.3.4 MYC in cell cycle and proliferation 
MYC expression is highly related to cell proliferation. Early studies in quiescent lymphocytes 
and rodent fibroblasts showed that MYC mRNA was promptly activated within 2 hours after 
mitogenic stimulation. This is typical for immediate early response genes such as FOS and 
JUN (Dean et al., 1986; Kelly et al., 1983; Reed et al., 1986). Further, quiescent rodent 
fibroblasts can re-enter cell cycle by ectopic expression of MYC even in the absence of serum 
factors, for instance by using the regulatable 4-hydroxytamoxifine-induced MycER system, 
showing that MYC is sufficient to induce cell cycle entry and progression (Eilers et al., 1991). 
Moreover, MYC is important for maintenance of the cell cycle, since depletion of MYC leads 
to cell cycle arrest in a variety of cell lines (Wang et al., 2008). MYC contributes to cell cycle 
progression through its transcriptional function; firstly, many factors encoded by MYC-target 
genes, e.g. cyclin D2 (CCND2), cyclin E1 (CCNE1), E2F1, and others promote this process. 
Secondly, MYC also inhibits the expression of CDK inhibitors p15, p21 and p27, e.g. 
through the assistance of MIZ-1 (Claassen and Hann, 2000; Seoane et al., 2002; Staller et al., 
2001; Wu et al., 2003).  
MYC also plays an essential role in S phase via by stimulating DNA replication. It has been 
reported that MYC can physically interact with the prereplicative complex (pre-RC) proteins 
CDC6 and minichromosome maintenance (MCM) proteins (Dominguez-Sola et al., 2007). 
Besides regulation of CDKs, which are involved in origin firing, MYC also favors opening of 
chromatin, which permits the loading of replication- related complexes (Dominguez-Sola and 
Gautier, 2014). Moreover, MYC can directly promote the recruitment of CDC45 to 
chromatin, leading to initiation of DNA replication (Dominguez-Sola et al., 2007; Sankar et 
al., 2009; Srinivasan et al., 2013).  
 
1.3.5 MYC in growth and metabolism 
Activation of cellular growth and cell cycle progression require dramatic changes in cellular 
metabolism, in which MYC also plays a major role. MYC is associated with different aspects 
of metabolism, including nutrient sensing and uptake, ribosome biogenesis, protein synthesis, 
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nucleotide synthesis and energetic metabolism (van Riggelen et al., 2010). First, MYC plays 
a critical role in glycolysis and glutaminolysis. MYC enhances uptake of glucose and 
glutamine via induction of glucose and glutaminase transporters. Moreover, MYC also 
activates other related factors. For example, MYC-induced monocarboxylate transporter 1 
(MCT1) is responsible to export lactate after conversion from glucose. Besides, MYC also 
promotes RNA splicing of pyruvate kinase M2 (PKM2) over PKM1, favoring glycolytic 
intermediates to be used in other biosynthesis pathways (Dang, 2013; Stine et al., 2015). In 
addition, MYC is also important for ribosome biogenesis and protein synthesis. In terms of 
ribosome biogenesis, first, among a wide range of MYC-induced RNAP II-transcribed genes, 
there are many mRNA encoding ribosomal protein (Fernandez et al., 2003; Orian et al., 2003). 
In addition, MYC also promotes transfer RNA (tRNA) expression via interaction with RNAP 
III transcription apparatus (Gomez-Roman et al., 2003). Besides, MYC also facilitates RNAP 
I-mediated ribosomal RNA (rRNA) transcription, thereby coordinating the activity of all 
three RNA polymerases (Arabi et al., 2005; Grandori et al., 2005). mRNA translation is also 
stimulated by MYC through increased expression of CAP-dependent translation initiation 
factors, e.g. eIF4E, eIF2α, eIF4AI and eIF4GI (Arabi et al., 2005; Schlosser et al., 2003; 
Schmidt, 2004). However, eIF4E stability is also prolonged by eIF4E binding protein 1 
(4EBP1), which is regulated by mTOR, another major regulator of protein synthesis besides 
MYC (Sonenberg and Hinnebusch, 2009). Therefore, eIF4E connects MYC and mTOR 
signaling. Moreover, MYC depletion suppresses deoxyribonucleoside triphosphate (dNTP) 
metabolism, via the reduction of corresponding rate-limiting enzymes, such as thymidylate 
synthase (TS), inosine monophosphate dehydrogenase 2 (IMPDH2) and phosphoribosyl 
pyrophosphate synthetase 2 (PRPS2) (Mannava et al., 2008). MYC also favors catabolism of 
excessive glutamine in order to sustain protein and nucleotide biosynthesis (Dang, 2010). 
Further, MYC also promotes mitochondrial biogenesis. It has been reported to regulate at 
least 18 mitochondrial genes and 400 nuclear genes encoding mitochondrial proteins, 
indicating an intricate link between MYC and mitochondrial biogenesis and metabolism 
(Coller et al., 2000; Kim et al., 2008; Schuhmacher et al., 2001; Seitz et al., 2011). Since the 
cell cycle, cell growth and metabolism need to be coordinated, it is obvious that MYC does 
not only activate expression of proliferative genes and genes involved in protein, nucleotide 
and lipid synthesis, but also accelerates the mitochondrial activity, such as increased oxygen 
consumption, mitochondrial membrane potential as well as mitochondrial mass, in order to 
support cell proliferation (Morrish et al., 2008; Schuhmacher et al., 1999).  
 
1.3.6 MYC in DNA damage response 
MYC overexpression can cause DNA damage via at least two types of routes. One is through 
the production of ROS, which is either directly induced as a consequence of MYC activity or 
indirectly by p53 activation in response to abnormal MYC expression (Polyak et al., 1997; 
Vafa et al., 2002). The other route is via replication stress. This is due to the deregulated S-
phase entry upon uncontrolled MYC expression, leading to replication fork stalling or 
collapse (Gorgoulis et al., 2005; Srinivasan et al., 2013). As a result of DNA damage, DDR is 
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triggered, majorly via ATM-CHK2 or ATR-CHK1 pathway (Maclean et al., 2007; Pusapati 
et al., 2006). The purpose of DDR is to repair damaged DNA to prevent mutations, however, 
if the damage is severe, this cell will undergo apoptosis or senescence in order to keep 
organism in homeostasis. If the DNA repair, apoptosis or senescence systems are deficient, it 
will result in genomic and chromosomal instability, eventually leading to tumorigenesis.  
 
1.3.7 MYC in apoptosis 
While promoting cell proliferation, MYC is also a potent inducer of apoptosis (Evan et al., 
1992). MYC is directly involved in both the intrinsic and extrinsic apoptosis pathways. For 
example, in the intrinsic pathway, MYC overexpression lead to suppression of anti-apoptotic 
genes BCL-2 and BCL-XL but induction of the pro-apoptotic genes BAX and BIM, thereby 
contributing to release of cytochrome C, caspase activation and apoptosis (Eischen et al., 
2001; Youle and Strasser, 2008). In addition, in the extrinsic pathway, MYC sensitizes cells 
to TNF-α-induced apoptosis, and promotes the association between BID and mitochondria to 
generate truncated BID (tBID), sequentially resulting in activation of pro-apoptotic BAX and 
BAK (Nilsson and Cleveland, 2003). Moreover, the p53 pathway also participates in MYC-
induced apoptosis. Firstly, MYC induces ARF expression, and the latter sequesters MDM2, 
which is involved in degradation of p53, thereby leading to stabilization of p53. Meanwhile, 
MYC also suppresses p21. In turn, the lack of p21 promotes the apoptotic function of p53 
over its cytostatic function (Henriksson et al., 2001; Li and Hann, 2009). Therefore, in order 
to overcome MYC-induced apoptosis, it is common that MYC overexpression in aggressive 
tumors is accompanied with BCL-2 upregulation (Martin-Subero et al., 2005; Mukhopadhyay 
et al., 2005; Seoane et al., 2002). In addition, it is very frequent that MYC-driven tumors 
carry mutant p53 (Henriksson et al., 2001; Nilsson and Cleveland, 2003). It has also been 
reported that more modest MYC levels in pre-malignant lesions promotes proliferation and 
transformation, while too high MYC levels will result in apoptosis, thereby aborting 
tumorigenesis (Murphy et al., 2008). However, disruption in apoptotic pathways, e.g. p53 
mutation or BCL2/BCL-XL overexpression, later in tumor development will allow higher 
MYC expression that will fuel high proliferation and aggressive tumor development.  
 
1.3.8 MYC in senescence regulation 
As mentioned before, activated RAS is known as a potent inducer of senescence trigger when 
overexpressing. However, MYC has been reported to counteract RAS-induced senescence in 
primary rodent cells (Hydbring et al., 2010; Larsson and Henriksson, 2010), which was 
shown to be dependent on CDK2-mediated phosphorylation of MYC at Ser 62 (Hydbring et 
al., 2010). Moreover, RAS also overcome MYC-induced apoptosis via activation of the 
PI3K/AKT pro-survival pathway. Therefore, cooperativity in rodent cells between MYC and 
RAS overrides two barriers of tumorigenesis-senescence and apoptosis, which contributes to 
transformation. Moreover, MYC expression can also overcome BRAFV600E-induced 
senescence in vivo, accelerating mouse lung tumor development (Tabor et al., 2014) as well 
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as BRAF- or NRAS-induced senescence in human melanoma cells (Zhuang et al., 2008). 
Further, it has been observed that MYC inactivation/depletion results in cell proliferation 
arrest, apoptosis and/or senescence in different experimental cancer models both in vitro and 
in vivo. This has led to the concept of MYC oncogene ‘addiction’ in certain tumors, where 
cancer cells become dependent on an overdose of MYC in cancer-related cellular processes 
compared with normal cells (Boxer et al., 2004; Felsher, 2010). The underlying mechanism 
of MYC downregulation-mediated senescence remains unclear (Wu et al., 2007; Zhuang et 
al., 2008). For example, the senescence by MYC-inactivation in osteosarcoma is independent 
on RAS-MAPK pathways and DNA damage response, which often play important roles in 
senescence regulation (Wu et al., 2007). Additionally, melanoma cells can also undergo 
senescence upon MYC depletion independent of two essential players for senescence-p53 or 
p16 (Zhuang et al., 2008). However, suppression of senescence by MYC seems to be cell 
context-dependent. In Werner syndrome fibroblasts, which lack of DNA repair function due 
to a mutation in WRN gene, MYC overexpression induces rather than suppresses senescence 
due to increased accumulation of DNA damage (Grandori et al., 2003). Another example is 
CDK2 knockout mouse embryonic fibroblasts (MEFs), where MYC induces senescence 
independent of DNA damage (Campaner et al., 2010). This may be seemingly contradictory 
with Hydbring et al., where CDK2 stimulated MYC’s suppression of senescence (Hydbring 
et al., 2010). Possibly, CDK2 acts as a switch, turning MYC from an inducer (when CDK2 is 
inactive) to a suppressor (when CDK2 is active) of senescence.  
 
1.3.9 MYC in immune response 
In addition to cell-intrinsic effect, such as promoting cell proliferation and cell growth, MYC 
overexpression has also been associated with tumor immune evasion. There are several 
studies revealing that MYC and MYCN regulate the gene expression of immune checkpoints- 
cluster of differentiation 47 (CD47, assisting cells to avoid phagocytosis (Majeti et al., 2009)) 
and PD-L1 (enhancing immune tolerance via binding to PD-1 (Tumeh et al., 2014)), leading 
to escaping immunosurveillance and promoting tumorigenesis in different tumor models, 
such as lymphoma, liver cancer, lung cancer and neuroblastoma (Atsaves et al., 2017; Casey 
et al., 2016; Kim et al., 2017; Melaiu et al., 2017). This effect can be reversed by interfering 
with MYC level, such as short hairpin-mediated MYC knockdown or BET inhibitor JQ1-
induced MYC repression, followed with restoration of immune response and tumor 
regression. MYC has been shown to regulate the expression of CD47 and PD-L1 via directly 
binding to their promoters. These studies confirmed that MYC oncogenic function is not only 
through promoting tumor cell proliferation but also through preventing tumor cell from 
immune attack, which uncovered the new facet of MYC in tumorigenesis. However, in order 
to obtain a precise view of MYC function in immune response, more studies need to be 
carried out. First, it is unclear whether this immune-related role of MYC is an oncogenic 
requirement or a physiological process. The occupancy of MYC in the promoters of CD47 
and PD-L1 occurs at a high MYC level, which would be due to ‘promoter invasion’, as a sign 
for oncogenic event. However, this may also happen in normal development of rapid cell 
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expansion, which upregulates NKG2D and is a risk to be attacked by immune system, 
therefore, MYC-mediated immune suppression is also required for rapid normal cell 
proliferation. Another thing is to clarify whether this is the only mechanism for MYC to 
suppress immune system or there are other routes. One possibility is through cytokines 
regulated by MYC, such as thrombospondin-1, involved in angiogenesis and senescence 
(Rakhra et al., 2010), and type 1 IFN (Schlee et al., 2007), associated with both innate and 
adaptive immunity. It has also been shown that in the KRASG12D-driven adenomas, MYC 
overexpression not only enhanced PD-L1 expression, but also promoted the secretion of 
CCL9 and IL-23 in stromal cells to suppress immune system, switching to proliferative and 
invasive adenocarcinomas (Kortlever et al., 2017). In addition, these immune suppressive 
properties also exist in other oncogenes, such as BRAF and β-catenin (Spranger et al., 2015; 
Sweis et al., 2016; Wilmott et al., 2012), which may converge to MYC- or other more 
parallel pathways-mediated immune suppression.  
 
1.3.10 MYC inhibitors 
Due to the predominant role of MYC in tumorigenesis, MYC seems to be an ideal therapeutic 
candidate. Therefore, researchers have tried to find ways to interfere with MYC either 
directly or indirectly. Because MYC is an intrinsic disordered protein and lack enzymatic 
activity, proteins like MYC are difficult to target. However, MYC function is dependent on 
binding to its obligated partner MAX. Thus, a possible strategy for targeting MYC is to target 
the MYC:MAX interaction. Quite some effort has been made from different labs, and several 
small molecules have been reported to inhibit MYC:MAX interaction, such as IIA4B20, 
10058-F4 and Mycro1 (Berg et al., 2002; Kiessling et al., 2006; Yin et al., 2003). But none of 
these compounds can be used clinically due to limitations, such as low potency in cells or in 
vivo or poor specificity (Fletcher and Prochownik, 2015; McKeown and Bradner, 2014; 
Prochownik and Vogt, 2010; Whitfield et al., 2017). However, our lab has identified and 
characterized two MYC:MAX inhibitors,  MYCMI-6 and MYCMI-7, which displayed good 
specificity and efficacy both in vitro and in vivo and are presented in paper III  (Castell et al., 
2018) and paper IV. There are also inhibitors reported to targeting MYC transcription, for 
instance BET bromodomain inhibitors such as JQ1 (Delmore et al., 2011) and I-BET 
(Chaidos et al., 2014; Dawson et al., 2011). BET proteins recognize acetylated histones 
within chromatin, and play a role in the recruitment of transcriptional regulators to activate 
gene transcription. In a certain context, such as murine leukaemia and multiple myeloma cells, 
BET proteins was reported to regulate the MYC gene directly, thus, upon BET inhibitors 
treatment, MYC expression was repressed (Dawson et al., 2011; Delmore et al., 2011; 
Filippakopoulos et al., 2010). However, in B-cell lymphomas, JQ1 treatment caused tumor 
suppression independent on the MYC level (Bhadury et al., 2014; Donato et al., 2017). 
Alternatively, exploiting MYC for synthetic lethality approaches could also contribute to 
anti-cancer therapy. Synthetic lethality is where deficiencies in two or more genes together 
causes cell death, while inactivation of either one alone does not. There are several reports 
that deregulation of MYC can be exploited to cause synthetic lethality. For example, since 
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overexpression of MYC causes replicative stress, targeting the DNA damage pathway, 
including proteins such as ATR and CHK1, results in accumulation of additional genomic 
instability and cause cell death (Cottini et al., 2015; Dominguez-Sola and Gautier, 2014). 
Moreover, since MYC reprograms cellular metabolism, thereby sensitizing cell to 
disturbances in metabolic alterations, inhibition of glutaminase has been reported to exert 
synthetic lethality with MYC, leading to cell death (Gao et al., 2009; Qing et al., 2012; 
Yuneva et al., 2007). Moreover, as mentioned above, inhibition of CDK2 in the context of 
MYC overexpression causes cellular senescence (Campaner et al., 2010; Hydbring et al., 
2010) or apoptosis (Molenaar et al., 2009). Undoubtedly, with a deeper understanding of the 
role of MYC in cell and tumor biology, different strategies will be developed in order to 
target MYC, eventually combating MYC-driven cancer. 
  
 31 
 
2 AIMS 
The overall aim of this thesis was to elucidate the potential of targeting MYC and other 
proteins connected to the MYC network for pro-senescence therapy as an alternative anti-
cancer treatment. Part of that task has been to elucidate the role of MYC in senescence 
regulation in normal human and malignant cells. Another part was to identify and 
characterize small molecules specifically targeting MYC in a number of cancer cell lines. 
 
The specific aims of each paper are as follows:  
Paper I: To explore the role of MYC in regulation of HRASV12-induced senescence in 
human normal fibroblasts.  
Paper II: To evaluate whether pro-senescence therapy could be an alternative strategy in 
melanoma treatment utilizing established and experimental targeting drugs.  
Paper III and IV: To characterize the small MYC:MAX inhibitory molecules MYCMI-6 
and MYCMI-7 with respect to efficacy and selectivity, and their potential in inhibiting MYC-
driven tumor cell growth.  
Paper V: To investigate the potential of experimental, pharmacological MYC inhibitors to 
induce senescence in melanoma cells, alone or in combination with other drugs. 
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3 RESULTS AND DISCUSSION 
3.1 PAPER I: MYC AND RAS ARE UNABLE TO COOPERATE IN 
OVERCOMING CELLULAR SENESCENCE AND APOPTOSIS IN NORMAL 
HUMAN FIBROBLASTS 
MYC and RAS are two of the best-documented oncogenes in tumorigenesis. However, they 
also trigger intrinsic tumor suppressor mechanisms, i.e. apoptosis and senescence, 
respectively, in order to dampen their tumorigenic function. From studies of rodent cells, 
MYC and RAS can cooperate with each other to overcome each other’s limitations. 
Coexpression of MYC and RAS is sufficient for transformation of primary rodent cells, but is, 
however, not sufficient for transformation of human primary cells, where additional 
oncogenic events are required. However, since overcoming apoptosis and senescence is 
necessary but not sufficient for transformation, it remains unclear whether in human primary 
cells, MYC and RAS still collaborate to overcome these fail-self mechanisms as in rodent 
cells.  
In Paper I, to explore this possibility, we utilized human primary BJ fibroblasts cells with 
tetracycline-induced HRASV12 and 4-hydroxytamoxifen (OHT)-regulated MycER system. In 
this system, doxycycline (DOX) binds to reverse tetracycline-controlled transactivator (rtTA), 
leading to transactivation of the HRASV12 gene, which is under the control of a promoter 
containing tet response element (TRE) (Evangelou et al., 2013; Maya-Mendoza et al., 2015). 
In MycER, the MYC gene is fused in frame to the ligand-binding domain of the estrogen 
receptor (ER). In the absence of OHT, chaperone proteins keep MycER in an inactive state. 
These proteins will be released upon addition of OHT, leading to activation of the MycER 
protein (Littlewood et al., 1995). 
HRAS-induced senescence was confirmed in BJ cells upon DOX treatment, with cell 
proliferation and cell cycle arrest, enlarged cell size and increased SA-β-GAL activity, as 
well as increased expression other senescence-related biomarkers, such as H3K9me3, p21 
and p16, and reduced phosphorylation of pRB. Upon MYC activation apoptosis was strongly 
induced, resulting in decreased cell number, increase of the percentage of dead cells, 
induction of DNA damage, p53 and increased PARP cleavage. Upon the dual induction of 
MYC and RAS, H3K9me3 and SA-β-GAL activity decreased somewhat, the expression of 
p16 increased further, compared to RAS induction alone. Therefore, MYC was unable to 
fully override RAS-induced senescence.  In addition, MYC activation also reduced the level 
of RAS, as well as the downstream effectors phospho-ERK (P-ERK) and phospho-AKT (P-
AKT), suggesting RAS pathway was tuned down by MYC. On the other hand, MYC-
triggered apoptosis remained at the same level after dual induction of MYC and RAS. This 
was not dampened by tuning down the OHT concentration or by scheduling the start of MYC 
activation to different time points after of RAS induction. Thus, RAS failed to overcome 
MYC-induced cell death in BJ cells.  
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Given the role of p53 in oncogene-induced apoptosis and senescence, and the upregulation of 
p53 upon MYC induction in our results, we assumed that p53 loss would be a possible way to 
rescue these cells. After establishment of a p53 knockdown cell line, we observed RAS-
induced senescence was overcome by p53 depletion, but MYC-triggered apoptosis was still 
not affected to any major extent, as shown by increased cleavage of PARP and cell death.  
It is known from previous work that MYC and RAS fail to transform human primary cells. In 
summary, our work now shows that MYC and RAS are unable to cooperate in overcoming 
even the first barriers of transformation, i.e. apoptosis and senescence. The main obstacle is 
apparently MYC-triggered cell death. A possible explanation is that the MYC-induced DDR 
signal is too strong and cannot be tolerated by cells, while the magnitude of pro-survival 
signaling, such as the RAS-induced PI3K/AKT pathway is still not sufficient or strong 
enough to abrogate MYC-induced cell death. One explanation for this is our observation that 
MYC activation dampened RAS-induced PI3K/AKT pathway. It has also been reported that 
activation of ERK can exert negative feedback signals to inhibit the RAS/MAPK pathway, 
which can be accelerated upon MYC induction (Shin et al., 2009). Hence, another possibility 
would be this negative feedback is stronger in human cells than in rodent cells, leading to the 
downregulation of RAS-signaling. Further, since ERK can phosphorylate MYC at Ser 62, 
which is important for survival upon DNA damage and for suppression of senescence by 
MYC (Benassi et al., 2006; Hydbring et al., 2010; Hydbring et al., 2017), down-modulation 
of RAS/MEK/ERK-signaling may restrain MYC function, leading to a vicious cycle. 
Additionally, the failure of p53 depletion to rescue MYC-induced cell death implies other 
factors, such as BCL2 and BCL-XL are required to override this aspect of MYC signaling in 
the context of human primary cells. Therefore, in human primary BJ fibroblasts, MYC and 
RAS failed to cooperate to reciprocally overcome cell death and senescence, and this was not 
affected by p53 knockdown.  
 
3.2 PAPER II: PRO-SENESCENCE THERAPY - A NEW STRATEGY TO 
OVERCOME DRUG RESISTANCE AND ENHANCE 
IMMUNORECOGNITION OF MALIGNANT MELANOMA CELLS 
The concept of therapy-induced senescence is built on observations that cancer cells often 
have an intact senescence induction system and retain the potential to senesce. Hence, based 
on to the tumor-suppressive and immunogenic function of senescence, we have utilized 
different established and experimental targeting drugs to address the question whether 
senescence can be established in human melanoma cells with different genetic backgrounds, 
and if so, whether there are differences in senescence phenotypes, SASP profiles and immune 
receptor expression of relevance for immunosurveillance between different drugs and/or 
genotypes, and finally, if pro-senescence therapy is a promising strategy for treatment of 
melanoma. 
In Paper II, to explore the potential of pro-senescence therapy in melanoma, we performed a 
senescence screen using a panel of eleven melanoma cell line with different common driver 
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mutations such as BRAFV600E, NRASQ61R, mutations enhancing the activity of PI3K or CDK4, 
or loss of PTEN or p53 activity. Ten selected targeted clinical and preclinical drugs of 
relevance for these mutations, such as vemurafenib (BRAFV600E inhibitor), trametinib 
(MEK1/2 inhibitor), BKM-120 (PI3K inhibitor), RITA (p53:MDM2 inhibitor), APR-246 (re-
activator of mutated p53) and palbociclib (CDK4/6 inhibitor), together with DNA alkylating 
agent temozolomide, which is a conventional drug used in melanoma therapy. Cells were 
seeded in 384-well plates, followed by three-day single drug treatment and 
immunofluorescent staining of several senescence-related markers were selected for the 
screen, including cell number, 5-ethynyl-2’-deoxyuridine (EdU) incorporation, cell area, 
nuclear area, intensity of H3K9me3 and p53 staining, as well as the immune marker HLA 
class I.    
Vemurafenib and trametinib displayed a good senescence response in two of four cell lines 
with BRAFV600E mutation, A375 and ESTDAB-049, while SKMEL28 and in particular 
ESTDAB-037 showed a poor response, indicating an intrinsic resistance to vemurafenib and 
trametinib in the latter. Vemurafenib were not effective for non-BRAF mutated cells as 
expected. Though trametinib suppressed cell growth in cells with NRAF mutation, the 
senescence response was not as good as the responsive BRAF-mutated cell lines. 
Temozolomide at conditions used was not sufficient to induce senescence in all cells. 
Interestingly, palbociclib, crizotinib and BKM120 arrested cell proliferation and induced 
senescence to different extent in all cells independent of BRAF/NRAS mutation. In terms of 
p53 activators, nutlin-3A and RITA induced senescence in most cell lines with wild type p53 
as expected, while APR-246 affected most cell lines wild type p53 and some with p53 
mutation. HLA class I expression was more evident upon palbociclib treatment in all cell 
lines except ESTDAB37 and KADA, and was enhanced upon crizotinib or nutlin-3A 
treatment in many cells. Thus, we found three drugs (palbociclib, crizotinib and BKM120) 
induced growth arrest and senescence in most of cell lines irrespective of their BRAF/NRAS 
status. 
Next we selected vemurafenib, trametinib, palbociclib and BKM120, for further validation 
using two BRAF mutant cell lines, A375 and ESTDAB-037, the NRAS mutant cell line 
SKMEL2 and two non-BRAF/NRAS mutated lines, ESTDAB-140 and KADA. The 
following markers were measured: cell number, cell cycle distribution, cell size, nuclear size, 
percentage of dead cells, SA-β-GAL activity, expression of H3K9me3, p53, phosphorylated 
pRb,  cyclin B, cleaved caspase 3 and SASP factors. It was confirmed that vemurafenib 
induced senescence in A375 but not in the ESTDAB37 BRAF-mutated line, and not in other 
cell lines. Trametinib, like vemurafenib induced senescence in A375, but also induced some 
markers of senescence in ESTDAB37. In the NRAS-mutated line SKMEL2, trametinib 
triggered many markers of senescence but almost no change in EdU incorporation or cell 
cycle distribution and also triggered cell death, suggesting a quite complex phenotype. 
Further, senescence induction was poor in the non-BRAF/NRAS-mutated cell lines after 
trametinib treatment. The PI3K inhibitor BKM120 affected some but not all markers of 
senescence in all cell lines, although the markers induced sometimes difference between cell 
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lines. Finally, palbociclib induced all senescence markers in all cell lines with few exceptions, 
irrespective of BRAF/NRAS status. Moreover, unlike most of the other drugs, palbociclib did 
not induce cell death, which makes palbociclib more of a general senescence inducer.  
We also examined the expression of SASP factors in response to the treatments, including 
AREG, CSF2, CXCL1, IL-1α, IL-1β, IL-6, IL-6R, IL-8 and MMP3. Among these factors, 
vemurafenib and trametinib induced only IL-6 in A375 but not in ESTDAB37 or other cell 
lines, except SKMEL2 where trametinib increased IL-6 and some other cytokines. BKM120 
and palbociclib had a much broader effect on SASP factor expression in most cell lines, but 
preferentially induced IL-1α/β, sometimes with CXCL1 and IL-8, while induction of AREG 
seemed to be more specific for BKM120. We also confirmed HLA class I expression, where 
vemurafenib only induced HLA class I in A375, while trametinib induced HLA class I in 
A375, ESTDAB37 and SKMEL2. BKM120 as well as palbociclib increased HLA1 in all 
cells, implying a potential for increased immunogenicity. 
We next wondered whether any combination treatment could overcome resistance to 
vemurafenib-induced senescence in BRAFV600E-mutant melanoma cell lines as well as 
resistance to trametinib. Therefore, we performed a second combination treatment senescence 
screen in 96-well plate format for three-day treatment, including vemurafenib or trametinib 
combined with each of all the other drugs at a serial dilution in five cell lines (A375, A375-
VR4 (acquired resistance to vemurafenib), ESTDAB-037, ESTDAB-140 and KADA). 
Subsequently, cell number, cell size and EdU incorporation was measured by 
immunofluorescent staining and imaged under a fluorescence microscope. The results 
indicated that palbociclib, crizotinib and BKM120 can synergize with vemurafenib to trigger 
senescence in both vemurafenib-sensitive and –resistant cell lines. 
Finally, since palbociclib, crizotinib and BKM120 alone induced senescence in most 
melanoma cell lines irrespective of BRAF/NRAS status, we were interested in whether 
combination of any of these drugs would synergize in senescence induction. We found that in 
particular the combination of palbociclib and crizotinib further enhanced senescence , which 
was confirmed by increased SA-β-GAL activity, reduced phosphorylated pRb and arrested 
proliferation in all the five cell lines. Further, the expression of certain SASP factors, 
preferentially on IL-1α/β, was increased with this drug combination irrespective of 
BRAF/NRAS mutation status. In addition, we also evaluated immune-related receptors for 
natural killer (NK) and T-cell recognition on A375, A375-VR4 and KADA cells. Upon 
palbociclib treatment, both HLA class I and class II, responsible for antigen-presenting to 
CD8+ and CD4+ T cells, respectively, were enhanced. The combination treatment further 
increased these two markers in KADA cells, but not in A375 and A375-VR4 cells. Moreover, 
PD-L1, inhibiting T cell function, was increased upon palbociclib treatment and further 
enhanced or stay the same level upon dual treatment. This suggested the combination 
treatment upregulated receptors for both T cell recognition and T cell suppression. In addition, 
ULBP2/5/6, ligands of NKG2D NK cell receptors, were also enhanced upon palbociclib 
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treatment and increased more with the addition of crizotinib in A375 and KADA, indicating 
combination also enhanced NK cell recognition. 
In summary, we found that palbociclib, BKM120 and crizotinib had the potential to trigger 
senescence in many cell lines irrespective of BRAF/NRAS mutations in our screen. In 
addition, these three drugs also were capable to overcome resistance to vemurafenib and 
trametinib. Moreover, upon the combination treatment of palbociclib and crizotinib further 
enhanced senescence in most of melanoma cell, linked to increased SASP factor expression 
and regulation of immune receptors of relevance for killing by T cells and NK cells. 
Pro-senescence therapy as an alternative strategy for anti-cancer therapy is under debate. In 
particular, the role of SASP factors needs to be clarified further. There are a number of 
publications arguing for the benefit of SASP factors. For example, different SASP factors, 
such as CCL2, TNFα and ICAM-1, can recruit NK cells and M1-like macrophages to clear 
senescent tumor cells (Iannello et al., 2013; Lujambio et al., 2013; Ruscetti et al., 2018; Xue 
et al., 2007). Moreover, dual inhibition of AURKA and MDM2 was reported to induce CCL5 
expression, leading to tumor clearance by the immune system in lymphoma model (Vilgelm 
and Richmond, 2015). However, the SASP is heterogeneous and for the most part pro-
inflammatory, which can cause chronic inflammation and promoter cancer development. It 
would therefore be interesting to validate our combination of drugs both in vitro and in vivo. 
Using immune cell killing assays one could investigate whether modulation of the protocol, 
for instance by including immunotherapy or a third targeted therapy, would improve the 
efficacy of the pro-senescence therapy. One should also investigate the immune response in 
melanoma mouse models in vivo in the future.   
 
3.3 PAPER III AND PAPER IV: CHARACTERIZATION OF SELECTIVE 
INHIBITORS FOR MYC:MAX INTERACTION MYCMI-6 AND MYCMI7 AND 
EVALUATION THE POTENTIAL IN INHIBITING MYC-DRIVEN TUMOR 
CELL GROWTH 
Given that MYC plays a crucial role in tumorigenesis with its partner MAX, we focused on 
developing inhibitors targeting the MYC:MAX interaction. Thus, we first performed a cell-
based screen for inhibitors of MYC:MAX interaction. The benefit with cell-based screens is 
that one can identify cell-permeable compounds with inhibitory activity in a cellular context 
already in the screening step, which is not possible using in vitro approaches. The screen was 
based on bimolecular fluorescence complementation (BiFC), in which full-length MYC and 
MAX were fused with two fragments of yellow fluorescent protein (YFP) separately. After 
transfection, MYC:MAX interaction will bring YFP fragments in close proximity in cells 
(Grinberg et al., 2004; Hu et al., 2002; Kerppola, 2006; von der Lehr et al., 2003). Through 
the screen, we found six compounds (MYCMI-2, MYCMI-6, MYCMI-7, MYCMI-9, 
MYCMI-11 and MYCMI-14) potentially targeting MYC:MAX interaction without affecting 
the BiFC interaction between the bZip transcription factors FOS and JUN. Two of them, 
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MYCMI-6 and MYCMI-7 were further characterized in Paper III and Paper IV, 
respectively.  
We also set up another protein-fragment complementation assay (PCA) assay for validation 
of these six compounds, in which full-length MYC and MAX were separately fused with two 
parts of the Gaussia luciferase (GLuc). Unlike BiFC assay, the interaction between these two 
fragments of luciferase are complementary but reversible, and emit a luminescence signal 
after catalyzing the cell permeable substrate coelenterate luciferin (Remy and Michnick, 
2006). All six compounds showed better inhibitory effects on both MYC:MAX and 
MYCN:MAX interactions at a concentration of 25 μM, compared to the previously reported 
MYC:MAX inhibitor 10058-F4 at 64 μM (Huang et al., 2006). None of the compounds 
affected homodimerization of the bZip transcription factor GCN4, thus confirming the 
selectivity of the compounds for MYC:MAX. Two of the molecules, MYCMI-6 and 
MYCMI-7, were the most efficient MYC:MAX inhibitors, and are the focus of Paper III and 
Paper IV, respectively. Since MYCMI-7, but not MYCMI-6, decreased the endogenous 
MYC level, the two molecules seem to work through different mechanisms. In Paper III, we 
focused on molecules that inhibit the MYC:MAX interaction without affecting MYC 
expression, and in Paper IV on MYCMI-7 that does both. 
In Paper III, we further validated MYCMI-6, MYCMI-11 and MYCMI-14. The three 
compounds targeted endogenous MYC:MAX interaction as shown by in situ proximity 
ligation assay (isPLA). In isPLA, after a pair of primary antibodies bind to the two interacting 
proteins of interest, secondary antibodies conjugated with DNA oligos are bound to primary 
antibodies, bringing the oligonucleotides in close proximity, provided that the two proteins 
interact in the cell. This allows hybridization between oligos and formation of a circular DNA 
template containing nicks, which are ligated together. After rolling circle amplification, 
oligonucleotides, which are coupled to fluorochromes and complementary to repeating 
sequences in the amplicons are used to detect sites of interaction. (Soderberg et al., 2006). In 
isPLA, the IC50 of MYCMI-6, MYCMI-11 and MYCMI-14 with respect to MYC:MAX 
interaction were found to be 1.5μM, 6μM and 6μM, respectively. The inhibitory effect of 
MYCMI-6 was measurable already after 3-hour treatment. U2OS cells containing MYC-ER 
was used to evaluate the effect of the compounds on MYC target gene expression. MYCMI-6 
significantly repressed three selected MYC target genes (ODC1, RSG16 and CR2), while 
MYCMI-11 and MYCMI-14 were less efficient. Next, to examine whether MYCMI-6 
targeted MYC:MAX directly, we performed biophysical interaction assays with recombinant 
bHLHZip domain of the MYC and MAX proteins. Here we first used microscale 
thermophoresis (MST), which is based on thermophoresis; the ability of fluorescent 
molecules to move in a temperature gradient, which will be affected by binding of ligands. 
Pretreatment with the three compounds perturbed the interaction between MYC and 
fluorophore-labeled MAX, and titration of MYCMI-6 showed a thermophoresis shift of 
Kd=4.3±2.9 μM for MYC:MAX, having only minor effect on MAX:MAX. In addition, 
surface plasmon resonance (SPR) was also performed to determine the affinity and monitor 
kinetics between protein and ligand. In SPR, the protein of interest is immobilized on a chip, 
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and the ligand of interest will flow over the chip surface. Upon binding of a ligand (or 
inhibitor) to the immobilized protein, changes will induced in the surface plasmon resonance , 
which can be measured (Schasfoort and Tudos, 2008). In this case, MYC or MAX was 
immobilized on a sensor chip. To explore the inhibition of MYC:MAX by MYCMI-6, the 
MAX bHLHZip was immobilized on the chip, and the MYC bHLHZip pretreated with or 
without MYCMI-6 was injected and allowed to flow over the chip. The IC50 of MYCMI-6 
inhibition of  MYC:MAX interaction was 3.8±1.2 μM, which was much more potent 
compared with the experimental MYC-MAX inhibitors 10058-F4 and KJ-Pyr-9 used as 
references. 
We next wanted to know if MYCMI-6 binds directly to MYC or MAX. By using the 
recombinant bHLHZip domain of MYC or MAX alone in the MST assay, we confirmed that 
MYCMI-6 bound to MYC, rather than to MAX, in the low micromolar range. This high 
affinity was also validated in SPR assay with immobilized MYC on chip. MYCMI-6 was 
shown to bind with a KD of 1.6±0.5 μM, in which KD of another two known MYC:MAX 
inhibitors 10074-G5 and #474 were 28 μM and 15 μM, respectively. MYCMI-6 binding to a 
number of other proteins, MAX, MXD1, p53 and BSA was negligible, and MYCMI-6 at 2 
μM only had 10% of the theoretical maximum to BCL-XL. Thus, MYCMI-6 directly and 
selectively bound to MYC bHLHZip domain with high affinity.  
We next evaluated whether MYCMI-6 could inhibit tumor cell growth and whether this 
correlated with MYC level. MYCMI-6 displayed a high efficacy to suppress the growth of 
MYC-driven tumor cells, e.g. neuroblastoma cells (GI50 ~2.5-6 μM) and Burkitt’s lymphoma 
(GI50= 0.5 μM) cells in vitro. MYCMI-6-mediated MYCN:MAX interruption was confirmed 
by decreased MYCN:MAX signals in isPLA and by suppression of MYCN target genes and 
anchorage-independent growth in MYCN-amplifed neuroblastoma cells. Moreover, we also 
found a strong correlation between MYC expression level and growth inhibitory response in 
NCI-60 tumor cell lines, in which cell lines with ‘higher MYC’ have significantly more 
probability to respond MYCMI-6 treatment than cells with ‘lower MYC’. Importantly, 
MYCMI-6 was not cytotoxic to normal human cells. In addition, MYCMI-6 reduced MYCN-
amplified neuroblastoma cell proliferation in a xenograft tumor model in vivo, partially 
resulting from MYCMI-6-triggered apoptosis. Data from isPLA also displayed a reduction of 
MYC:MAX interaction upon MYCMI-6 treatment in vivo. Therefore, MYCMI-6 suppressed 
MYC function in MYC-driven tumor cells via selective disruption of MYC:MAX interaction, 
leading to cell proliferation arrest and apoptosis.  
In terms of MYCMI-7, we also confirmed inhibition of endogenous MYC:MAX interaction 
using the isPLA assay, and co-immunoprecipitation assay showed that this interruption 
started already within an 1 hour of treatment, suggesting a prompt inhibition of MYC:MAX 
interaction mediated by MYCMI-7, without affecting MYC protein level at early time points. 
Chromatin immunoprecipitation (ChIP) assay also revealed that MYCMI-7 led to 
dissociation of MYC from promoters of MYC target genes starting already at 2 hours post 
treatment. Interrupting MYC:MAX also led to repression of the MYC target gene CR2 in 
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U2OS-MycER system. Using recombinant bHLHZip domain of MYC and MAX in SPR also 
indicated that MYCMI-7 inhibited MYC:MAX interaction directly and bound to MYC with 
an affinity of approximately 4 μM. 
We next addressed the mechanism of the reduced endogenous MYC expression observed 
after prolonged treatment with MYCMI-7. Our results showed that MYCMI-7 decreased the 
MYC protein level but did not affect the mRNA expression. While MYCMI-7 increased 
MYC protein turnover somewhat in HCT116 cells it did not seem to affect the turnover rate 
in Hela cells, suggesting that this is cell-context-dependent. FBW7 is known to induce 
degradation of MYC by binding Thr 58-phosphorylated MYC, but phosphorylation of Thr 58 
or Ser 62 was not been altered, and MYC T58A and S62A mutants were still reduced in 
expression after upon MYCMI-7 treatment, which argues that FBXW7 is not directly 
involved in MYCMI-7 action. Another possibility is that MYCMI-7 affects the MYC mRNA 
translation process, which requires further investigation. 
We next studied if MYCMI-7 affected cell growth in a MYC-dependent manner. For this 
purpose, we used in Rat1 fibroblasts with different MYC status (wild-type MYC, MYC null 
and reconstituted MYC), Both MYCMI-6 and MYCMI-7 inhibited growth of wt and MYC-
reconstituted cells, but not MYC null cells, thus showing that the compounds inhibited 
growth in a MYC-dependent manner. Similar to MYCMI-6, MYCMI-7 preferentially 
inhibited growth of MYCN-amplified compared with non-amplified neuroblastoma cells. It 
also strongly inhibited growth of Burkitt’s lymphoma cells with MYC translocation, and a 
good correlation was found between MYCMI-7 inhibition and MYC expression level in NCI-
60 human tumor cell line panel. Further, while MYCMI-7 only had a cytostatic effect on 
normal cells, it triggered apoptosis in tumor cells, thereby showing a good therapeutic 
window. Using an ex vivo cell panel derived from primary glioblastoma tumor biopsies from 
42 patients, MYCMI-7 induced growth inhibition with an EC50 in the submicromolar range, 
and growth inhibition was also observed in primary acute myeloid leukemia (AML) tumor 
biopsies. In addition, MYCMI-7 also reduced tumor burden in an MYC-driven AML 
allogeneic mouse model. Further, in a basal-like breast cancer xenograft model and MYCN-
amplified neuroblastoma xenograft model, besides tumor regression, MYCMI-7 also 
prolonged survival. In summary, MYCMI-7 inhibits MYC:MAX inhibition with high 
efficacy in cells and in vitro, binds recombinant MYC directly at low mM concentrations, 
downregulates MYC protein expression, inhibits MYC-driven tumor cell growth in vitro and 
in vivo resulting in reduced tumor burden and increased survival in vivo. 
The comparison between MYCMI-6 and MYCMI-7 indicated different mechanisms probably 
mediated by two MYC:MAX inhibitors. Unlike MYCMI-6, MYCMI-7 not only inhibited 
MYC:MAX interaction, but also decreased steady state of MYC level in different cell lines. 
The reason for this difference is unclear. Though both of them target the MYC bHLHZip 
domain, the precise binding sites may be different. This may for instance affect the folding of 
the proteins differently, which may affect how the proteins are targeted for proteolysis. It is 
also possible that either compound affects the interaction between MYC and also other 
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MYC-binding proteins, which also may have different outcomes. Another possibility would 
be that the compounds also have other targets other than MYC:MAX. All these require 
further investigation. 
 
3.4 PAPER V: MYC INHIBITORS WORK SYNERGISTICALLY WITH BRAF, 
MAPK AND CDK INHIBITORS TO BLOCK MALIGNANT MELANOMA CELL 
GROWTH BY INDUCTION OF CELLULAR SENESCENCE 
MYC expression is commonly deregulated in cancer and often linked to aggressive disease, 
including in melanoma (Beroukhim et al., 2010; Ciriello et al., 2013), which makes MYC as 
a prioritized target for anti-cancer therapy. However, there are no specific MYC inhibitors 
available in clinic. This motivated us to pursue a screening campaign for more efficient and 
selective MYC inhibitors, leading to the identification of  MYCMI-6 (Paper III) (Castell et 
al., 2018) and MYCMI-7 (Paper IV). MYC inhibition is reported to induce senescence in 
melanoma cells with BRAF/NRAS mutation (Zhuang et al., 2008). In Paper V, we explored 
the potential of the MYC:MAX inhibitor MYCMI-7, as well as other experimental MYC 
inhibitors, including two MYC:MAX inhibitors10058-F4 (F4) and MYCMI-6, a BET 
inhibitor JQ1, which represses MYC transcription in certain cells, to induce senescence in 
melanoma cells as potential pro-senescence therapy.  
First, we performed a senescence screen using MYCMI-7 and F4, and the same panel of 
melanoma cells as in Paper II. Compared to F4, MYCMI-7 displayed a more potent growth 
inhibitory effect and induced signs of senescence in the majority of cell lines, preferentially 
those with BRAFV600E mutation. In addition, MYCMI-7 also enhanced HLA class I 
expression at higher doses. Senescence induction was further validated using selected cell 
lines with BRAFV600E mutation and three MYC inhibitors, MYCMI-7, F4 and JQ1. We found 
that the different MYC inhibitors exerted different effects in terms of senescence and 
apoptosis induction. For example, in A375 cells, F4 was a potent trigger of DNA damage and 
apoptosis 24 hrs post treatment without activating p53 or p21, while MYCMI-7 induced p53 
activation already at lower dose as well as p21, indicative of senescence induction, but caused 
apoptosis only at higher dose. In contrast, JQ1 triggered high expression of p21 without 
induction of apoptosis. Interestingly, unlike F4 and JQ1, MYCMI-7 suppressed cell growth 
persistently after drug removal. The BRAFV600E inhibitor vemurafenib and the MEK inhibitor 
trametinib are used clinically for melanoma treatment, but patients eventually develop 
resistance to these treatments. In order to evaluate if the MYC inhibitors influenced 
vemurafenib/trametinib resistance, a senescence screen was performed using BRAF or MEK 
inhibitors in combination with MYC inhibitors. The results showed that the MYC inhibitors 
synergized with BRAF inhibitor/MEK inhibitors to induce senescence and overcome 
vemurafenib-induced resistance in most cases. In Paper II, we found the CDK4/6 inhibitor 
palbociclib induced senescence in most melanoma cell lines, irrespective of BRAF/NRAS 
mutations. We therefore explored the potential of combining palbociclib and MYC inhibitor 
treatments to overcome vemurafenib-induced resistance. The results showed that the 
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combined treatment displayed a synergistic effect in inducing senescence in melanoma cells, 
also in vemurafenib-resistant cells. In addition, combinations of the MYC inhibitors with the 
traditional DNA alkylating agent temozolomide or the experimental p53:MDM2 inhibitor 
RITA were also effective in some but not all cell lines.  
Our results confirmed a previous publication by Zhuang et al. that siRNA-mediated depletion 
of MYC triggered senescence in melanoma cells (Zhuang et al., 2008), and extended this to 
experimental pharmacological MYC inhibitors. However, we also observed some differences 
in effects among the different pharmacological MYC inhibitors. For example, at least in 
A375 cells, F4 seemed favor apoptosis over senescence, MYCMI-7 treatment resulted in a 
mix of senescent and apoptotic cells, while JQ1 preferentially induced signs of senescence. 
However, only MYCMI-7 induced a persistent growth inhibitory effect compared with F4 
and JQ1. One explanation for these differences could be that JQ1 targets MYC transcription, 
while the other compounds inhibit the MYC:MAX interaction but also downregulates MYC 
protein levels, presumably through different mechanisms (Paper II (Castell et al., 2018) and 
Paper III). Moreover, F4 and MYCMI-7 treatment both induced DNA damage, which could 
trigger both apoptosis and senescence dependent on cell context, while JQ1 did not. Since 
JQ1 is a BET inhibitor, it is likely to affect a number of other genes apart from MYC, which 
may also contribute to the outcome. Also, one cannot exclude that F4 and MYCMI-7 have 
other targets as well. 
Interestingly, palbociclib showed a good synergistic effect with the MYC inhibitors, 
including MYCMI-6, with respect to senescence induction, which potentially could provide 
an alternative treatment strategy in the future in drug-resistant melanoma. CDK4 is a well-
known MYC target gene (Hermeking et al., 2000) and the oncogenic function CDK4 and 
MYC were mutually dependent on each other for malignant transformation (Haas et al., 1997; 
Miliani de Marval et al., 2004), indicating a close cooperation between CDK4 and MYC. 
Therefore, targeting these two factors should have synergistic effects, as shown here. 
Moreover, there are implications about the role of MYC in the temozolomide and RITA 
treatment from previous research. Regarding the synergism between MYC and temozolomide, 
temozolomide has been suggested to inhibit human glioblastoma via suppression of MYC 
and activation of TAp63 (Yamaki et al., 2013). RITA and MYC inhibitors did show a good 
dose-dependent senescence induction in A375-VR4 cells with synergistic effects. Given that 
A375-VR4 cells have wild type of p53, RITA-mediated senescence may work through 
reactivation of p53, alternatively by triggering the DNA damage response, which in turn 
activate p53 as an effector (Ahmed et al., 2011; de Lange et al., 2012), leading to senescence 
induction. This may partially overlap with mechanisms of F4/MYCMI-7-induced senescence, 
resulting in synergism. Further, dual treatment of RITA and another BET inhibitor CPI-203 
synergized chronic myeloid leukemia (CML) undergoing cell death, differentiation and 
elimination of leukaemic stem cells (Abraham et al., 2016). Thus, the combination of 
palbociclib, temozolomide or RITA with MYCi may improve treatment for drug-resistant 
melanoma. 
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Moreover, one important feature of senescence is SASP, and therefore it would be intriguing 
to examine the expression of SASP and additional immune markers both in vitro and in vivo 
upon MYC inhibition, to uncover the potential of anti-MYC pro-senescence therapy with 
immunosurveillance activation. Intriguingly, it has been confirmed that both CD47 and PD-
L1 are MYC target genes, leading to immune evasion of tumor cells (Casey et al., 2017; 
Casey et al., 2016; Xu et al., 2019). These could be downregulated upon JQ1 treatment and 
result in immune stimulation and tumor regression (Casey et al., 2016; Zhu et al., 2016a). In 
addition, Kortlever et al. also reported that MYC overexpression led to recruitment of 
macrophages, expelled T and B cells and favored angiogenesis due to secretion of CCL9 and 
IL-23, and PD-L1 induction, eventually switching KRASG12D-driven adenomas into 
proliferative and invasive adenocarcinomas (Kortlever et al., 2017). Thus, targeting MYC 
with other factors can be a win-win opportunity to both arrest cell proliferation and re-
establish immunosurveillance.   
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